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ABSTRACT
Validation of the 40 Hz Auditory Steady State Response as a Pharmacodynamic Biomarker of
Evoked Neural Synchrony
by
Muhammad Ummear Raza
Schizophrenia is a troubling and severe mental illness that is only incompletely treated by
currently available drugs. New drug development is hindered by a scarcity of functionally
relevant pharmacodynamic biomarkers that are translatable across preclinical and human
subjects. Although psychosis is a major feature of schizophrenia, cognitive and negative
symptoms determine the long-term functional outcomes for patients. Stimulus-evoked neural
synchrony at gamma (~ 40 Hz) frequency plays an important role in the processing and
integration of sensory information. Not surprisingly, schizophrenia patients show deficits in
gamma oscillations. NMDA receptor (NMDAR) activation on fast-spiking parvalbumin-positive
interneurons is deemed important for the generation of gamma oscillations. NMDA hypofunction
has been proposed as an alternative hypothesis to the well-known dopamine dysregulation to
explain the neurochemical abnormalities associated with schizophrenia. For this dissertation, we
validated a preclinical model to pharmacologically probe NMDA-mediated gamma oscillations
by further characterizing the auditory-steady state response (ASSR) in female Sprague Dawley
rats. The ASSR is a measure of cortical neural synchrony evoked in response to periodic auditory
stimuli. ASSR at 40 Hz is consistently disrupted in patients. First, we established the reliability
of click train-evoked 40 Hz ASSR and tone-evoked gamma oscillations in 6 separate sessions,
spread over a 3-week period. Then we established the sensitivity of these neural synchrony
measures to acute NMDAR blockade using the high affinity NMDA channel blocker MK-801,
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using a repeated measures design. Next, we compared the reliability and sensitivity of the 40 Hz
ASSR from two distinct recording sites. Results from this study showed that as compared to
vertex, temporal recording showed a greater gamma synchrony. However, the temporal
recording had poor test-retest reliability and lower sensitivity to MK-801-induced disruption.
Lastly, we characterized the dose-response profiles of an NMDA co-agonist D-serine, an atypical
(clozapine) and a typical (haloperidol) antipsychotic, on the 40 Hz ASSR. Results from these
studies showed that only clozapine was effective in robustly augmenting 40 Hz ASSR.
Furthermore, only clozapine pretreatment had partial protective effect against MK-801 induced
ASSR disruption. Overall, this work establishes that vertex recorded 40 Hz ASSR is a reliable
neural synchrony biomarker in female SD rats that is amenable for bidirectional
pharmacodynamic modulation.
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CHAPTER 1. INTRODUCTION
Overview
Schizophrenia is a debilitating psychiatric illness affecting nearly 1% of the world
population (Ropper et al. 2019). People with schizophrenia experience distorted reality, altered
perception, blunted sensory and emotional experiences, and exhibit poor social skills. In clinical
parlance, patient experiences such as hallucinations, delusions, disorganized thinking, and speech
are referred to as positive symptoms, while inability to experience normal emotions coupled with
a flattened affect are referred to as negative symptoms. Social and/or neurocognitive deficits
constitute the third core feature of this disease.
In 1911, Eugen Bleuler, a Swiss psychiatrist, coined the term schizophrenia (Bleuler
1911; Moskowitz and Heim 2011), which consists of two Greek words skhizein (to split) and
phrēn (mind), referring to the fragmentation of psychological functioning that he observed in
patients (Fusar-Poli and Politi 2008). Earlier, a German psychiatrist, Emil Kraepelin had
described a distinct psychotic condition, different from other forms of psychosis, and named it
“dementia praecox” (Kraepelin 1899; Falkai et al. 2015), which Bleuler challenged by calling it
neither dementia, nor something precocious. The pioneering works of Kraeplin and, especially
Bleuler, presented for the first time a diagnosis of mental illnesses based on psychology, which
later influenced the symptoms-based classification of psychiatric disorders leading to the 1st
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-I) (Andreasen 1989).
Even after more than 100 years of treatment and research related to schizophrenia,
diagnosis is still based on symptoms as defined in the latest edition of DSM (DSM-V) (American
Psychiatric Association 2013). Pharmacotherapy involves the use of antipsychotics that show
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partial efficacy against positive symptoms and fail to improve negative and cognitive symptoms
to any substantive extent (Murphy et al. 2006; Tandon et al. 2009; Tandon et al. 2010).
Moreover, most of the currently used antipsychotics fail to work in a significant fraction of
patients (classified as treatment-resistant) and are associated with serious side effects (Miyamoto
et al. 2012).
Unfortunately, there is no comprehensive understanding about the pathophysiology of
schizophrenia. There is, however, a growing understanding that schizophrenia may be a
neurodevelopmental disorder shaped by genetic and environmental factors (Lewis and Levitt
2002; Demjaha et al. 2012; Wahbeh and Avramopoulos 2021).
At present, there is a lack of objective biomarkers that can inform diagnosis or
establish treatment efficacy (Weickert et al. 2013; García-Gutiérrez et al. 2020). In the last few
decades, there has been a trend towards characterizing schizophrenia-associated neural processes
for the development of reliable biomarkers, an approach to transition away from a symptomsbased heuristic. There is an expectation that the development of neural-based biomarkers will
lead to a more specific targeting of biological abnormalities underlying schizophrenia (AbiDargham and Horga 2016; Light et al. 2020), leading to a more rational understanding and
treatment of the disease. Additionally, disease-relevant neural circuit performance-based
measures are critical for new drug development as they can highlight a particular abnormality
objectively and attempt to correct it through pharmacological or other types of interventions.
Historically, a major focus of schizophrenia research has been to manage psychotic
symptoms because of their overt and aversive nature, while the negative and cognitive symptoms
have not been a center of attention. Yet, it is now widely accepted that both negative and
15

cognitive symptoms have a more profound bearing on long-term patient outcomes, such as how
well they are able to be a part of a community and function with a degree of independence
(Harvey et al. 2006; Yang et al. 2021). Availability of validated neural circuit function
biomarkers that impact these hitherto neglected symptom domains may lead to the development
of new and improved therapies (Spellman and Gordon 2015). More specifically, to address the
negative and cognitive symptoms of schizophrenia that directly determine the overall functional
outcomes of treatment (Fett et al. 2011; Green and Plaza 2016; Z. Yang et al. 2021).

Schizophrenia Symptoms
As outlined above, schizophrenia represents a complex mental illness exhibiting a
spectrum of symptoms that are classified into three major domains, positive, negative, and
cognitive. Positive symptoms refer to the most apparent mental dysfunction such as
hallucinations (a tendency to misattribute perceptual experiences to the outside environment),
and delusions, or strongly held beliefs that are not based in reality. Negative symptoms involve
apathy/avolition (lack of motivation), anhedonia (inability to feel pleasure), social withdrawal,
and flattened affect. Cognitive symptoms involve an inability to pay attention, disorganized
thoughts (thought disorder), limited verbal fluency, and poor short/long term memory
(Andreasen 1995; van Os and Kapur 2009; Ropper et al. 2019). The onset of the first episode of
psychosis often happens between early adolescence to young adulthood, typically, with an earlier
onset in males than in females (Ochoa et al. 2012). Around 75% of the individuals go through a
prodromal phase and present psychotic symptoms at a subthreshold level for up to 1 year (Häfner
et al. 2003; Sørensen et al. 2009), before they suffer an acute episode leading to a hospital
admission and diagnosis. A significant body of data now indicates that cognitive symptoms
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precede psychosis and represent a core feature of the disease (Kahn and Keefe 2013; Üçok et al.
2013; McCleery and Nuechterlein 2019). Moreover, psychotic symptoms flare up as acute
episodes and subside, while negative and cognitive symptoms persist throughout the duration of
the illness (Harvey et al. 2006).

Etiology

Genetic Factors
As stated earlier, both genetic and environmental factors contribute to the etiology of
schizophrenia. Even though the rate of incidence is approximately 1% in the general population,
the probability of occurrence of schizophrenia in a first-degree relative of a patient is 8-fold
higher. This goes up to 11-fold, if two first-degree relatives are affected (Le et al. 2020). If one
monozygotic twin develops schizophrenia, the other has a 50% overall likelihood of developing
the same (an incidence rate of 41-65 %, measured as concordance rate), while in fraternal twins,
this incidence can range between 0-28 %. Moreover, monozygotic twin studies report a genetic
heritability for schizophrenia of up to 80-85% (i.e., genetic contribution explains 80% of the
50% overall likelihood) (Cardno and Gottesman 2000; Sullivan et al. 2003).
While epidemiological studies show a strong genetic component, no single allele/locus is
known to markedly increase susceptibility. Genome-wide association studies (GWAS) have
resulted in more than 100 loci associated with schizophrenia, with each locus having a minor
contribution, thus further reinforcing the multifactorial and complex etiology of schizophrenia
(Dennison et al. 2020). The only exception, however, is 22q11.2 deletion syndrome, which
causes a ~25-fold increase in the risk of developing schizophrenia. That is, approximately 25%
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of the individuals with the deletion ultimately develop schizophrenia symptoms (Cleynen et al.
2020). Other than genetic, environmental influence accounts for about 10-20% risk for
schizophrenia (Cardno and Gottesman 2000), thus suggesting an important role for environmentmediation during perinatal development. Different environmental factors that have shown to be
associated with schizophrenia include, but not limited to, obstetric complications (Cannon et al.
2002), prenatal infections (Cheslack-Postava and Brown 2021), adverse childhood experiences
(Varese et al. 2012), migration (Henssler et al. 2020), and cannabis use (Wainberg et al. 2021).

Neurodevelopmental Factors
Both genetic and environmental factors may contribute to cause aberrant brain
development. A meta-analysis of the neuroimaging data obtained from more than 5000 healthy
controls and 4000 schizophrenia patients showed a significant reduction in the thickness and
surface area of the temporal and frontal lobes in patients (van Erp et al. 2018). In the normally
developing brain, there is a constant process of balanced synaptic growth and pruning. Through
the first few decades of life, the white matter representing myelinated axons increases in volume,
while there is a general reduction in gray matter representing the pruning of the dendritic
processes and neuropil.
Another important aspect of normal development is the gradual increase in inhibitory
synapses, that prevent runaway excitation in the cortical circuits and help maintain an optimal
excitatory/inhibitory (E/I) balance. One theory posits that abnormal neurodevelopmental
processes during childhood involving excessive pruning and a significant reduction in the
number inhibitory synapses may result in the emergence of schizophrenia in adolescence (van
Erp et al. 2018). Several genes associated with schizophrenia as reported by genome-wide
18

association studies (GWAS) play an important developmental role; for example, genes such as
dysregulated in schizophrenia 1 (DISC1), neuregulin 1 (NRG1), and its receptor ErbB4
(ERBB4), dysbindin (DNTBP1), and reelin (RELN) are integral to synaptogenesis and plasticity
(Harrison and Weinberger 2005) and get highlighted as variants in schizophrenia patients. Early
exposure to environmental factors like stress and certain drugs can exacerbate the sensitivity of
aberrant circuits to certain neurotransmitters, biasing towards psychosis (Niemelä et al. 2016;
Popovic et al. 2019). Thus, it is thought that genetic and environmental factors interact to
increase the susceptibility to schizophrenia by skewing a normal neurodevelopmental trajectory
towards illness.

Neurochemical
On the other hand, the neurochemical imbalance hypothesis offers an explanation where
regional alterations in key neurotransmitters’ activity is implicated in the manifestation of
schizophrenia symptoms, as proximate cause.
The dopamine hypothesis. Dopamine is one of the key neurotransmitters in the brain that
regulate important behaviors like reward, motivation, executive function, and motor control
(Robbins and Arnsten 2009; Bromberg-Martin et al. 2010). It is synthesized in the substantia
nigra (SN) and ventral tegmental area (VTA) of the brain. Dopaminergic neurons from these two
areas project to diverse brain regions principally through nigrostriatal, mesolimbic, and
mesocortical projections. The dopamine hypothesis suggests that the positive symptoms arise
due to dopamine hyperactivity in the mesolimbic pathway, while negative and cognitive
symptoms arise due to hypoactivity of dopamine in the mesocortical pathway (Fabiana et al.
2008).
19

The dopamine hypothesis originated after the discovery of dopamine as a
neurotransmitter by Arvid Carlsson in 1958 (Carlsson et al. 1958). Subsequently, Carlsson’s
group reported that the prototypical antipsychotics, chlorpromazine and haloperidol, block the
dopamine (D2) receptors, a critical milestone in formulating the dopamine hypothesis (Carlsson
and Lindqvist 1963). Subsequent studies established a correlation between the clinical efficacy
of all the available antipsychotics to their D2 receptor binding (Creese et al. 1976; Seeman et al.
1976). Indeed, D2 receptor affinity and blockade of the D2 receptors at therapeutic
concentrations is the most parsimonious explanation for the efficacy of all the clinically effective
antipsychotic drugs to date. Moreover, dopamine-releasing drugs like amphetamine were shown
to induce psychotomimetic effects in humans and primates (Bell 1973; Ellison et al. 1981),
strengthening further the evidence for this hypothesis.
Further support comes from studies showing that schizophrenia patients show dopamine
dysregulation in the mesolimbic and mesocortical areas (Perez-Costas et al. 2010; Lodge and
Grace 2011; Yoon et al. 2013). While postmortem histopathological studies and antemortem
neuroimaging studies have reported contradicting results regarding the density of dopamine
receptors in schizophrenia patients (Farde et al. 1987; Lahti et al. 1996; Seeman et al. 1997;
Seeman and Kapur 2000), imaging analyses of drug-naïve schizophrenia patients consistently
show striatal dopaminergic hyperactivity (Abi-Dargham et al. 2000; Patel et al. 2010).
Notwithstanding the evidence summarized above, antipsychotics that block D2 receptors
and blunt subcortical hyperdopaminergia, are only partially effective against schizophrenia
symptoms (Gründer and Cumming 2016). One of the reasons for this is that dopamine
dysregulation is not pathognomonic as schizophrenia patients show neurochemical
heterogeneity. That is, imbalance may be noted with several neurotransmitters, not just dopamine
20

(Yang and Tsai 2017). This is further supported by the fact that one of the most effective
antipsychotics, clozapine (or atypical antipsychotics in general), shows a relatively low affinity
for D2 receptors (Seeman et al. 1997). Thus, there is a reason to explore other neurotransmitter
systems that may be equally important in causing schizophrenia pathophysiology, one of which
is glutamate (Kristiansen et al. 2007; Bubenikova-Valesova et al. 2008; Balu 2016).
The glutamate hypothesis. In the late 1950s and 60s, it was observed that certain drugs
like phencyclidine (PCP) can induce schizophrenia-like symptoms in chronic users and
aggravate schizophrenia symptoms in patients (Luby et al. 1959; Davies and Beech 1960; Cohen
et al. 1962; Itil et al. 1967). PCP disrupts glutamate neurotransmission by blocking N-methyl-Daspartate receptors (NMDAR). According to the glutamate hypothesis, NMDAR hypofunction
leads to a disruption of glutamate signaling and results in schizophrenia symptoms. Noncompetitive NMDAR inhibitors like PCP and ketamine not only induce positive symptoms but
also negative and cognitive symptoms, which implicate glutamate transmission in phenotypes
resistant to D2-based antipsychotics (Snyder 1980; Javitt and Zukin 1991; Carter et al. 1997).
The NMDAR hypofunction also reconciles the dopaminergic dysregulation outlined above. For
example, NMDAR dependent cortical activity inhibits dopamine release in the limbic regions
while promoting its release in the cortical areas (Schwartz et al. 2012). Therefore, a reduced
NMDAR tone in the cortical circuits has a disinhibitory effect on the dopamine
neurotransmission in the mesolimbic circuit (hyperdopaminergia), and a net inhibition on the
dopamine release in the mesocortical pathway (hypodopaminergia). Thus, according to the
glutamate hypothesis of schizophrenia, the dopamine dysregulation is secondary to NMDAR
hypofunction.
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Postmortem examination of the dorsolateral prefrontal cortex region of the brain from
schizophrenia patients has noted a reduced density of NR1 subunit, an obligatory component of
the NMDAR channel (Vibeke et al. 2015; Vibeke et al. 2016). This evidence for reduced
NMDA-dependent glutamate signaling was shown to correlate with cognitive deficits (Weickert
et al. 2012). However, it must be noted that some studies have found no change or increased
expression of NMDAR in the nucleus accumbens and dorsolateral prefrontal cortex,
respectively, suggesting a brain region-specific alteration of glutamate signaling (Dracheva et al.
2001; Lum et al. 2018). The increase in NMDAR may be an adaptation secondary to reduced
glutamate release. Indeed, genetic analysis has shown an association of single nucleotide
polymorphisms (SNPs) in many genes associated with glutamate signaling (Kirov et al. 2011;
Weickert et al. 2012; Fromer et al. 2014). These findings support an etiological role for regionspecific dysregulation of NMDAR transmission in schizophrenia.
Even though NMDARs are expressed on both pyramidal and GABAergic interneurons,
NMDAR antagonists at low concentrations seem to preferentially affect GABAergic
interneurons, especially the parvalbumin (PV; a calcium-binding protein) expressing subtype
(Lewis and Moghaddam 2006). This may be because the interneurons receive a higher number of
glutamatergic inputs as compared to any other type. Furthermore, PV+ neurons show higher
baseline activity and a relatively more depolarized membrane potential, as compared to
pyramidal neurons. Thus, making them prone to the removal of Mg2+ “plug” from the NMDA
channel pore, and therefore more susceptible to NMDA open channel blockers like MK801
(Lewis and Moghaddam 2006). Preferential inhibition of NMDAR on the GABAergic neurons,
by NMDAR antagonists reduces inhibitory control or disinhibits the excitatory pyramidal
neurons, leading to hyperexcitation of the cortical circuits and an increase in the E/I ratio
22

(Homayoun and Moghaddam 2007; Cohen et al. 2015; Zorumski et al. 2016). Modeling studies
have illustrated how an overall increase in E/I ratio results in localized circuit dysfunction and an
inability to integrate context-specific cues (Calvin and Redish 2021). In summary, according to
the NMDAR hypofunction hypothesis, poor NMDA-based GABAergic activation leads to
disinhibition of the pyramidal neurons and skews the E/I balance towards an increase resulting in
disruption of cortical processing and schizophrenia symptoms.

Animal Models Of Schizophrenia
The development of suitable animal models for schizophrenia is essential to improve our
current understanding of schizophrenia pathophysiology, as well as to enable novel drug
development. Thoughtfully developed animal models can provide valuable information about the
molecular, structural, and electrophysiological abnormalities relevant to schizophrenia leading to
the identification of new drug targets and candidates. However, the development of animal
models for schizophrenia also poses challenges due to the following reasons. 1. Schizophrenia is
heterogeneous (i.e., clinical symptoms are diverse, genetic/epigenetic influences are manifold,
and disease progression is uneven), and a complex (i.e., overlapping symptoms with other
psychiatric conditions, significant comorbidities, many subtypes included under the same
definition) human mental condition. 2. There is an incomplete understanding of the underlying
neurobiological abnormalities (Powell and Miyakawa 2006).
A neurobiological approach to psychiatric conditions suggests that these are a result of a
dysfunctional network response. Disrupted neural systems affect both human and animal
behavior and share cross-species homology that may not be the case with overt behavior or
symptoms. Thus, animal models may be developed that can mimic network dysfunction similar
23

to schizophrenia, even if they do not replicate the same symptoms or behavior. The human
relevance of these animal models can be addressed through a validity analysis.
Three important types of validity are construct, predictive and face. The soundness of
theoretical rationale for the interventions in animal models, which should be human diseaserelevant, is addressed by construct validity. Predictive validity is concerned with how well the
outcomes after intervention in animal models predict similar outcomes in human disease.
Whereas face validity assesses the replication of biophysical and behavioral features of human
disease in animal models (Marcotte et al. 2001; Jones et al. 2011). While modeling symptoms or
behavior in animals, face validity may present a remarkable challenge vis-a-vis schizophrenia
and other psychiatric diseases as well. For example, replication of cognitive symptoms in less
cognitively developed animals, limits face validity. Similarly, animal models of depression like
the forced swim test and tail suspension test have been criticized for questionable face validity
(Cryan and Mombereau 2004; Slattery and Cryan 2014). On the other hand, certain elementary
psychophysiological (e.g., startle) or neurophysiological responses (sensory gating) seen across
species and believed to underlie a feeling of “sensory information overload” in patients, may be
well suited for cross-species translation, especially if they have pathophysiological relevance
(Swerdlow et al. 2008).
Animal models of schizophrenia have been created through genetic, pharmacological,
physical, and neurodevelopmental interventions. As described previously, monozygotic twin
studies show up to 80-85% heritability for schizophrenia, suggesting a strong genetic
contribution (Cardno and Gottesman 2000). However, there are very few disease-associated
alleles with high penetrance enough to cause illness in a predictive manner. GWAS have
revealed several genes that interact to influence glutamatergic and dopaminergic pathways, as
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well as affect processes like synaptogenesis, immune modulation, intracellular signaling, and
neural plasticity. Some of the more common alleles include DAT, NR1, DISC1, NRG, ERBB4,
DNTBP1, and RELN (Jones et al. 2011). Phospholipase C-β1 (PLC-β1) disruption is another
genetic approach used in rodents to mimic schizophrenia-like phenotypes (Kim et al. 2015).
Neurodevelopmental disruption using physical, pharmacological, and behavioral
interventions in rodents undergoing perinatal development has been an important approach for
developing animal models. Behavioral interventions include causing maternal separation-related
distress in neonates or their post-weaning social isolation (Jones et al. 2011). Developmental
interventions that use neurotoxicants involve the injection of methylazoxymethanol acetate
(MAM), an antimitotic agent, or the bacterial endotoxin lipopolysaccharide (LPS), or relatively
large doses of the NMDA antagonists, administered to pregnant dams (du Bois and Huang 2007;
Bubeníková-Valešová 2008; Lim et al. 2012). MAM specifically targets the neuroblast
proliferation and migration in the CNS, which leads to anatomical and behavioral deficits (Jones
et al. 2011). LPS induces immune activation in the maternal circulatory system that affects brain
development. There is some evidence that maternal infection during pregnancy can be a risk
factor for schizophrenia in the offspring (Brown and Derkits 2010; Brown 2011). Perinatal
administration of quinpirole, a dopaminergic D2 agonist, has been reported to result in longlasting D2 receptor sensitization and associated behaviors reminiscent of schizophrenia
(Kostrzewa et al. 2016). Other models involve administering relatively large doses of NMDA
antagonists to neonates during early development (e.g., postnatal days 7-15) (Plataki et al. 2021).
Acute pharmacological interventions rely on blocking glutamatergic transmission acutely
through modest doses of the NMDAR antagonists like PCP, MK801, or ketamine. Other
pharmacological models involve using dopamine agonists like amphetamine (Featherstone et al.
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2008; Steeds et al. 2015). However, the amphetamine model has been criticized for its
incompleteness as amphetamine-induced psychosis mimics the positive symptoms characteristic
of schizophrenia, but not negative and cognitive symptoms (McCutcheon et al. 2020), a
shortcoming not associated with acute NMDA antagonism, which replicates all three
characteristic symptom domains (Krystal et al. 1994). Nearly all the above-reviewed approaches
result in behavioral phenotypes that have some phenotypic relevance to schizophrenia and
therefore have translational value (Steeds et al. 2015).

Biomarkers In Schizophrenia Research
A biomarker is “a defined characteristic that is measured as an indicator of normal
biological processes, pathogenic processes, or biological responses to an exposure or
intervention, including therapeutic interventions” (FDA-NIH Biomarker Working Group 2016).
The biomarker working group excluded individual feeling, function, or survival from the
definition of a biomarker. However, a biomarker can include “molecular, histologic,
radiographic, or physiologic characteristics” (FDA-NIH Biomarker Working Group 2016). As
described earlier, diagnosis of schizophrenia relies on either DSM-V or International Statistical
Classification of Diseases and Related Health Problems, Eleventh Edition (ICD-11).
As mentioned earlier, schizophrenia presents a challenge for diagnosis, treatment, and
drug development due to reliance on a symptoms-based approach and lack of etiological
information underlying the disease. This is further complicated by the heterogeneous nature of
the disease. Schizophrenia patients show a large degree of overlap in symptoms with patients of
other mental illnesses and suffer with significant comorbidities (Buckley et al. 2009). These
factors complicate diagnosis and pose a challenge to effective treatment development. There is a
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need for biomarkers-based approach that can provide pathophysiological insight, can help in
diagnosis, and in stratifying individuals based on the underlying pathophysiology for targeted
treatment options.
Additionally, biomarkers are invaluable as critical goalposts to guide new drug
development. They are needed for confirming target engagement, proof of concept studies as
well as for dose selection during preclinical lead evaluation as well as during early-stage clinical
development. These drug development-related applications are the ones that are most pertinent
to the current dissertation.
Owing to the complex and heterogeneous nature of schizophrenia, individual
schizophrenia symptoms are isolated and modeled in animals as simple, quantifiable, and
singular behavioral measures. For example, hyperlocomotion in animals is proposed to replicate
the condition of psychosis in humans, a reflection of the hyperdopaminergia in the mesolimbic
circuit (Jones et al. 2011). Moreover, a subset of acutely ill patients does exhibit psychomotor
agitation and stereotypy, justifying the use of hyperlocomotion as a behavioral measure (Powel
and Miyakawa 2006). Sucrose preference is used to model negative symptoms like anhedonia
(Muscat and Willner 1989), whereas tests of social interaction are used to model social
withdrawal (Sams-Dodd 1998). Animal models are tested for working memory tasks or attention
for cognitive deficit evaluation. Although the above behavioral measures are proposed to
represent objective, quantifiable features replicating individual schizophrenia symptoms in
animal models, it is unclear how well they represent these symptoms. For example, a lack of
preference for a sweet treat is unlikely to be a specific, dependable, and accurate indicator of
anhedonia. Besides, there are many confounding factors that can affect these measures, which
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should be carefully controlled. For example, hyperlocomotion may have a non-specific effect on
sucrose preference expression or a working memory performance.
More recently, there has been increased attention to develop and test schizophreniaassociated endophenotype responses, as an intermediate between a behavioral phenotype
(disease symptom) and the underlying putative genotype and its cellular biochemical expression.
An endophenotype is a hidden feature that is responsive to, and discoverable by testing. It is a
quantitative measure of a heritable biological trait. It is stable and shows a close association to
the underlying pathophysiology of the disease, unlike clinical symptoms that may wax and wane
(Gottesman and Gould 2003). Widely used endophenotypes in schizophrenia research involve
sensorimotor gating (pre-pulse inhibition of startle (PPI)), sensory gating response like P50 or
N100, event-related potentials such as mismatch negativity (MMN), and P300 (ERP) (Gottesman
and Gould 2003; Hamilton et al. 2018). Such endophenotypes reflect the function of discrete
neural circuits. For example, PPI represents activation of the limbic cortex, striatum, pallidum,
and pontine tegmentum (CSPP) regions (Swerdlow et al. 2001), while sensory gating reflects
inhibitory neurotransmission in the hippocampus (Cromwell et al. 2008). More recently,
researchers have focused on neural oscillations as an endophenotype to examine dysfunctional
neural circuits in a layer-specific and cell-type-specific manner.

Neural Oscillations
The moment-to-moment neural activity in the cortical layers of the brain is reflected as
the oscillatory electrical potential. Changes in electrical activity can be recorded through
electroencephalography (EEG), while fluctuations in the magnetic field can be recorded through
magnetoencephalography (MEG) (Beppi et al. 2021). EEG is the most widely used clinical tool
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to probe the activity of cortical circuits in real time. It is non-invasive and provides temporal
resolution in milliseconds. However, EEG has limited spatial resolution, which means relative to
other imaging modalities like PET or fMRI, EEG is a poor indicator of the source of neural
activity (Srinivasan 1999; Burle et al. 2015). This is especially the case when one or only a few
scalp electrodes are used to record EEG. While it is challenging to decipher the spatial source of
the electrical activity, methods such as low-resolution electromagnetic tomography or LORETA
have been developed to compute neural sources from a large number of scalp electrodes (>64)
through mathematical modeling (Pascaul Marqui et al. 1994). While it is possible to get excellent
spatial resolution through an array of electrodes placed directly on the brain surface (e.g.,
electrocorticography or ECoG) or by recording local field potentials (LFPs) (Buzsáki et al.
2012), such methods are invasive and are viable only under some special conditions in humans.
Neural oscillations recorded through EEG reflect fluctuations in the electrical activity of
a large population of cortical neurons. Hans Berger first developed the method to record EEG in
humans in the 1920s. Transmembrane ion fluxes in large populations of cortical neurons result in
real time changes in the extracellular field potential, which travel as a wave and can be recorded
noninvasively from the scalp surface. Additionally, electrical activity produced by the
synchronized firing of cortical neural populations is captured as periodic oscillations of the EEG
(Buzsáki and Wang 2012).
Neural oscillations provide information regarding different vigilance states (e.g., alert or
somnolent) of the brain and are consistent across mammalian species, making them ideal
translational biomarkers (Buzsáki et al. 2013; Javitt et al. 2020). When considering a neural
oscillatory signal (or any wave-like signal, for that matter), there are three important variables to
consider: magnitude (or signal power), frequency, or number of cycles per second and phase of
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the oscillation relative to some temporal event like stimulus onset. EEG oscillations are classified
into canonical frequency bands called delta (0.5-4 Hz), theta (4-9 Hz), alpha (9-13 Hz), beta (1330 Hz), gamma (30-90 Hz), and epsilon (> 90 Hz) (Buzsáki 2006; Freeman 2007; Keavy et al.
2016).

Gamma Oscillations
Gamma oscillations have a frequency range of 30-90 Hz. They are thought to play an
essential role in sensory processing, higher cognitive and behavioral processes (Buzsáki and
Wang 2012). Over the years, studies on animals and humans have revealed a major role of
gamma oscillations in bottom-up, top-down, and sideways information processing in the cortical
circuits (Uhlhaas and Gray 2010). Gamma oscillations are especially important in cognitive
functions. The so-called binding by synchrony theory explains the fundamental role of gamma
oscillations in synchronizing activity across discrete brain regions involved in processing a
common task (Gray et al. 1989; Singer and Gray 1995). Through gamma oscillations, distinct
brain regions can integrate and coordinate information processing (Roelfsema et al. 1997;
Tallon-Baudry and Bertrand 1999; Ghiani et al. 2021). For example, while traveling in a car, a
flashing red light and a distant siren may immediately trigger the memory of an ambulance and
make you move to the side. While each of these stimuli are processed by discrete cortical
regions, the visual cortex for flashing light, auditory cortex for the sound, prefrontal cortex in
deciding to move to the side, it is believed that they are processed as a common percept and
gamma oscillations are critical for rapidly binding activity in spatially and functionally discrete
regions of the brain, processing the same task (Carr et al. 2012). Another illustration of the role
of gamma oscillations in cognitive processing has to do with working memory tasks. During a
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working memory task, as an individual mentally holds a piece of information (e.g., a phone
number or a house address) and recalls it after a brief delay, the brain regions involved in this
process show gamma oscillatory activity. Moreover, the working memory performance
correlates with the strength of the gamma signal over the delay phase (Howard et al. 2003). Such
studies highlight the role of gamma oscillations in integrating perceptual experience as well as in
enabling cognitive performance. Before moving forward, a brief description of the three
important types of gamma oscillations is in order.
1: Spontaneous gamma. As the name suggests, these gamma oscillations are generated through
the spontaneous activity of the neural populations. These oscillations are also called baseline or
ongoing gamma and are generally independent of external stimuli. Typically, an increase in
vigilance is associated with an increase in spontaneous gamma while slow-wave sleep correlates
with low gamma activity (Amir et al. 2018).
2: Evoked gamma. This type of gamma oscillations are produced in response to an external (or
an internal) event or stimulus. Evoked gamma oscillations show a time-locked relationship to the
presented stimulus. For example, a brief auditory tone evokes a burst of gamma oscillatory
activity, time-locked to the stimulus.
3: Induced gamma. This type of gamma oscillations are also dependent on external or internal
stimuli. However, while induced gamma oscillations are temporally related to the stimulus, they
are not strictly time locked in the way the evoked oscillations are. For example, when a brief
tone elicits evoked gamma as above, it is accompanied by a different kind of gamma oscillations
that are triggered by the tone but are not time-locked to it. Thus, in repeated trials, induced
gamma appears around the time of the tone but are not strictly time-locked to it and tend to get
diminished with averaging.
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Generation Of Gamma Oscillations
Two models have been proposed to explain the generation of gamma oscillations: these
are the interneuron network mediated gamma (ING) and pyramidal-interneuron network
mediated gamma (PING) models. A schematic of both ING and PING model-based neural
interactions are depicted in fig. 1.1.
In the ING model, gamma oscillations are generated through the interaction of two
reciprocally connected interneuron populations (fig. 1.1-A). In this arrangement, when one
interneuron population depolarizes as a result of an excitatory input, it feed-forwards inhibitory
impulses to the second population, which undergoes hyperpolarization. When the second
population depolarizes, the first group is inhibited. It takes ~25 milliseconds (ms) for the
inhibited interneurons to recover due to the decay time constant of GABAA receptors. Thus,
these interconnected neurons fire at a ~25 ms interval, giving rise to gamma oscillations (Wang
and Buzsáki 1996; Buzsáki and Wang 2012).
The ING model was developed after studies showed that the power of gamma oscillations
was associated with the firing rate of hippocampal interneurons, and tonic depolarization of
interneuron populations in the hippocampus and cortex resulted in the generation of gamma
oscillations (Buzsáki et al. 1983: Whittington et al. 1995). Later, optogenetic studies have
confirmed that depolarization of fast-spiking (FS) interneurons is sufficient to generate gamma
oscillations, while their prolonged hyperpolarization attenuates gamma oscillations (Sohal et al.
2009). Further support comes from in vitro studies that show, reciprocal inhibitory interaction
between interneurons, through the GABAA receptor, are sufficient for the generation of gamma
oscillations (Whittington et al. 1995).
32

The PING model on the other hand generates gamma oscillations because of interaction
between the excitatory pyramidal neurons and the inhibitory interneurons (fig. 1.1-B). Thus,
while pyramidal neurons feed-forward excitatory inputs to the interneurons, the interneurons
impinge inhibition on the perisomatic segments of the same pyramidal neurons. Thus, in effect,
the activated interneurons restrict the pyramidal cells to fire only when there is a near complete
decay of the inhibitory input (~25 ms), leading to regular oscillations at the gamma frequency.
Therefore, in PING networks, interneurons make it less likely for pyramidal neurons to fire
randomly. Moreover, through this interaction, interneurons maintain the E/I balance in the
cortical circuits. The PING model is supported by gene mutation and optogenetic studies in
animals.

A

B

Figure 1.1. ING and PING models for the generation of gamma oscillations. In the Interneuron
Network Gamma (ING) model (A), the interneurons spontaneously fire periodically at ~ 40 Hz
(i.e., due to GABAA decay time constant of ~25 ms). The reciprocal inhibitory feedback
between these interneurons shunts any random activity and thus results in a synchronized firing
giving rise to gamma oscillations. In the Pyramidal Interneuron Network Gamma (PING) model
(B), gamma oscillations arise due to the interaction between glutamatergic pyramidal neurons
and GABAergic interneurons via excitatory and inhibitory interaction. Interneurons are driven by
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excitatory inputs from the pyramidal neurons, which in return are synchronized by perisomatic
feedback inhibition by the interneurons. (I) Inhibitory GABAergic neuron, (E) excitatory
pyramidal neuron.

Depolarization of pyramidal neurons in the cortical circuits through optogenetic
stimulation induces gamma oscillations (Yizhar et al. 2011; Lu et al. 2015; Bitzenhofer et al.
2017). Moreover, gamma oscillations can also be induced by stimulating NMDAR specifically
on the interneurons (Mann and Mody 2009). Genetic ablation of the NR1, an obligatory subunit
of the tetrameric NMDA receptor complex, results in entrainment deficit at gamma frequencies
(Carlén et al. 2012). These findings suggest a vital role of NMDAR- dependent excitatory
stimulation from the pyramidal neurons in generating gamma oscillations and provide support
for the PING model.
There is a diverse variety of fast spiking (FS) interneurons based on electrophysiological,
neurochemical, and morphological properties (Tremblay et al. 2016). Among the FS
interneurons, basket cells that project onto the perisomatic region of the pyramidal neurons in
cortical layers 2/3 are important for the generation of gamma oscillations. Specifically, the
basket cells that are PV+ have been shown to be strongly associated with the generation of
gamma oscillations (Buzsáki and Wang 2012). Recent optogenetic studies have shown that
depolarization of PV+ interneurons facilitates gamma oscillations, while hyperpolarization of
PV+ neurons results in a reduction in gamma power (Cardin et al. 2009). Moreover, phasic
stimulation of PV+ neurons in the cortical layers 2/3 by light pulses at gamma frequencies
evoked a faithful field gamma response at that frequency, suggesting that these neurons are also
the most likely target for entrainment with rhythmic sensory input, such as an auditory click
train. The importance of PV+ interneurons is further highlighted by the fact that schizophrenia
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patients consistently show a reduction in PV+ cells in the layers 2/3 of the cerebral cortex, which
is associated with gamma deficits (Gonzalez-Burgos et al. 2015), as described below.

Gamma Oscillations In Schizophrenia
Cognitive deficits represent one of the major symptom domains in schizophrenia
(Heinrichs and Zakzanis 1998; Bora et al. 2009; Tripathin et al. 2018; Mascio et al. 2021). As
outlined above, gamma oscillations correlate with cognitive functions such as processing of
sensory input, working memory, and attention (Tallon-Baudry and Bertrand 1999; Singer 2004;
Tallon-Baudry 2009). If gamma oscillations are causally linked to cognitive function, it is
reasonable to hypothesize that schizophrenia patients with cognitive deficits will have
abnormalities in gamma oscillations. Indeed, studies using visual or auditory stimulus paradigms
have shown that schizophrenia patients indeed exhibit deficits in synchrony and power of gamma
oscillations (Spencer et al. 2003; Spencer et al. 2008). Moreover, schizophrenia patients show
reduced gamma activity during cognitive tasks (e.g., working memory) as compared to healthy
controls (Basar-Eroglu et al. 2007; Karch et al. 2009; Minzenberg et al. 2010). There have also
been studies showing the correlation of gamma deficits in schizophrenia patients with real-world
functional outcomes (Cho et al. 2006; Shin et al. 2011; Keil et al. 2016; Zhou et al. 2018;
Koshiyama et al. 2020; Molina et al. 2020). Thus, these studies point to the clinical and
functional consequence of gamma deficits.
As described previously, PV+ neurons play an important role in generating gamma
oscillations. PV+ interneurons, and glutamic acid decarboxylase (GAD67), an enzyme important
for GABA synthesis, show reduced immunoreactivity in specific cortical regions in the
postmortem brain of schizophrenia patients (Beasley and Reynolds 1997; Beasley et al. 2002;
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Reynolds et al. 2002). Notably, this loss is lamina specific with layer 2/3 of the supragranular
cortex being the most affected (Beneyto and Lewis 2019). Other studies, however, have shown
that patient brains may have reduced immunoreactivity for PV protein while not affecting the
cellular density (Hashimoto et al. 2003; Woo et al. 2006; Enwright et al. 2018). For example,
Hashimoto and colleagues (2003) showed that when compared to healthy subjects, the PFC of
schizophrenia patients have reduced mRNA levels of PV protein per cell, which was highly
associated with reduced expression of GAD67, while there was no significant reduction in the
total number of PV+ neurons (Hashimoto et al. 2003). Overall, there is substantial evidence that
supports that the functioning of PV+ neurons is reduced in schizophrenia in a laminar-specific
manner (Kaar et al. 2019). PV+ neurons express NMDAR, making them susceptible to NMDAR
antagonists. Studies have shown that administration of NMDAR antagonists in awake rats results
in the reduced firing of fast-spiking interneurons (Homayoun and Moghaddam 2007). Genetic
ablation of NR1 subunit, an obligatory subunit of NMDAR, specifically on the PV+ neurons,
results in the reduction of locally generated gamma oscillations (Carlén et al. 2012) as well as
reduced entrainment to rhythmic stimuli. Furthermore, schizophrenia patients show reduced
expression of the NR1 mRNA and protein in their brains (Catts et al. 2016). Other studies have
shown that sustained NMDAR antagonism in rodents attenuates PV mRNA and GAD67
expression (Cochran et al. 2003; Behrens et al. 2007), mimicking PV and GAD67 reductions
seen in schizophrenia (Lewis et al. 2005). Thus, the NMDAR hypofunction hypothesis links the
disruption of NMDAR on PV+ neurons to gamma deficits seen in schizophrenia.

36

Stimulus-Evoked Response (SER)
When a discrete stimulus, either as a somatosensory, visual, or auditory event is
repeatedly presented as trials to a human or animal subject, an EEG response, called stimulusevoked response (SER) is obtained by averaging such trials (Sörnmo and Laguna 2005).
Averaging of the EEG response trials ensures canceling out of the background electrical activity
unrelated to the stimulus, and only the consistent stimulus-dependent, time-locked response
remains. SER represents the sensory processing of the stimulus information in the neural circuits;
thus, it is a valuable tool to measure the structural and functional integrity of these pathways
(Brenner et al. 2009). EEG response to a stimulus can be classified into two categories: transient
response and steady-state response (SSR). Transient response results after the presentation of a
transient stimulus like a brief tone or a single click. Whereas presentation of periodic or rhythmic
stimuli like a click train results in an SSR. Unlike the transient response, which is short-lived,
SSR shows a sustained response to the periodic/isochronic stimuli that is constant in amplitude
and phase for the duration of the stimulus, a so-called steady-state response (Brenner et al. 2009).

Auditory-Evoked Response (AER)
Evoked response in the form of a time-locked change in EEG that remains after
averaging a number of trials in response to auditory stimulation is called auditory-evoked
response, or potential (AER/P). AER can be a transient response or auditory steady-state
response (ASSR) that lasts as long as the train stimuli. In humans, the transient response shows
several peaks and troughs over a duration of 300 milliseconds (fig. 1.2). It includes auditorybrain stem response (ABR; occurs with 2-10 ms latency), middle latency response (MLR; 15-60
ms), and late latency response (LLR; 50-300 ms), following the onset of the auditory stimulus
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(Melcher 2009). ABR is generated by the electrical activity in the auditory nerve and the brain
stem auditory nuclei like the superior olives and the inferior colliculus. MLR represents the
activity of thalamocortical pathways whereas the LLR captures the activity of primary and
secondary auditory cortices, as well as association and frontal cortices (Moore 1987; McGee et
al. 1991). Thus, the ABR, MLR, and LLR with different latencies, show the ascending
transmission of auditory signals from the inner ear to the cortical regions.
ABR consists of seven positive peaks (I-VII) with different latencies depending on the
auditory stimulus and mammalian species (Jewett and Williston 1971; Stapellst et al. 1984).
ABR is independent of the arousal state and thus, it is not affected by sleep or anesthesia. It is
used to measure the hearing threshold in infants, ascertain neurological problems in the auditory
pathway like lesions or tumors, and for diagnosing hearing disorders (Young et al. 2022). ABRs
are generally well preserved in schizophrenia patients, suggesting that infra thalamic auditory
pathway function is not affected by this condition. MLR has two positive and two negative peaks
named as Na-Pa and Nb-Pb. MLR is influenced by the state of arousal, and thus, under
anesthesia, shows higher latencies and lower peak amplitudes. MLR is also used to ascertain
hearing threshold, determine the depth of anesthesia, assess the postoperative integrity and
function of cochlear implants, and localize lesions in the auditory pathway (Kraus et al. 1982;
Özdamar and Kraus 1983). Lastly, LLR show positive and negative peaks named P1, N1, P2,
and N2 (Backer et al. 2019). P1 is often interchanged with Pb component of the MLR due to
time overlap, however different neural generators are responsible for Pb and P1, and they show
different developmental trajectories. This suggests that P1 and Pb components may indicate
different attributes of auditory processing (Ponton et al. 2002). Mammals like cats, rats, and
guinea pigs show AERs similar to humans, with a proportional change in latency due to the size
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and length of the conduction pathways. For example, the P1 latency is around 50 ms after tone
onset in humans and its equivalent in rodents tends to be around 20 ms. Similarly, the prominent
negative deflection called N1 happens in humans around 100 ms after stimulus onset while it
happens around 40-50 ms after tone onset in rodents (Umbricht et al. 2004) (fig. 1.3). From the
foregoing, it is apparent that given the similar sensory processing across mammals and the
morphological similarities of the AERs, they are reasonable measures to study stimulus-evoked
auditory event processing in humans and rodents.

Figure 1.2. Diagram of the auditory-evoked response in humans recorded at electrode Cz.
Adapted from Folmer et al.., 2011.

39

Figure 1.3. Comparison of latencies of AER’s P1, N1 and P2 in mice and in human subjects.
Reproduced with permission from Umbricht et al., 2004.
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Auditory Steady-State Response (ASSR)
A single click or tone stimulus elicits a transient EEG response, as outlined above, that is
comparable across human and preclinical species. This response happens as momentary
deflections in the EEG potential. However, when this response is analyzed for spectral content
through signal processing techniques such as fast Fourier transforms or wavelet-based timefrequency analysis (Markovic et al. 2012), one can isolate many distinct canonical oscillatory
frequencies (e.g., delta, theta, alpha etc.) that underlie the response. Owing to this frequency
content, the AER is considered as a broadband signal. In contrast to the AER, a train of discrete
clicks presented at a given frequency and duration elicit a response that is constant in amplitude
and phase and reflects the driving frequency and its duration (Regan 1989; Brenner et al. 2009).
Additionally, ASSR starts off with a transient broadband oscillatory signal, much like a response
from a single click. However, this is followed by a gradual buildup of an entrainment response
that is limited to a narrow driving frequency and lasts as long as the train stimuli. Thus, an
ASSR, once established, has a signal/noise (S/N) ratio advantage over transient stimulus-evoked
responses like single clicks or pips since the transient responses are broadband and so is the
background EEG signal or “noise”. In contrast, the ASSR signal is narrowband and mimics the
driving frequency even as the background “noise” continues to be broadband. The ASSR has
been interpreted as the linear superposition of transient AERs evoked by individual click stimuli,
as explained by the linear superposition theory of ASSR generation (Galambos et al. 1981;
Bohórquez and Özdamar 2008; Presacco et al. 2010; Capilla et al. 2011). However, several
studies have raised questions about the superposition theory by showing that simple
superposition did not account for the observed ASSR accurately (Suzuki et al. 1994; Azzena et
al. 1995; Conti et al. 1999).
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An alternative mechanism called the entrainment theory suggests that phase
synchronization and resetting of the ongoing oscillating neural field potential to match the
driving frequency of the steady-state stimuli is the basis for the ASSR (Ross et al. 2005; Thut et
al. 2011; Lütkenhöner and Patterson 2015). According to the entrainment theory, cortical circuits
have a preferred resonance frequency, and auditory stimulation induces the most
synchronization/entrainment at that frequency (Galambos 1982; Başar et al. 1987). Recent
studies give strong support to the entrainment/phase synchronization hypothesis (Light et al.
2006; Presacco et al. 2010; Capilla et al. 2011; Koenig et al. 2012; Griskova-Bulanova et al.
2014; Tada et al. 2016).

40 Hz ASSR As A Biomarker In Schizophrenia
ASSR, especially at gamma frequency (~40 Hz), shows the highest magnitude and is
consistently reduced in schizophrenia (Spencer et al. 2008; Hamm et al. 2011; Rass et al. 2012;
Picton 2013; Thuné et al. 2016), and in people at risk for schizophrenia (Rass et al. 2012; Tada et
al. 2016). Thus, the 40 Hz ASSR is regarded as both a schizophrenia state as well as a
schizophrenia trait marker. Through 40 Hz ASSR, cortical neural circuits can be activated to
generate gamma oscillations, and thus, 40 Hz ASSR is a tool to probe not only the integrity of
the auditory sensory processing, but also the synchronization of the cortical neural circuits to a
gamma driving frequency (Teale et al. 2003; Light et al. 2006; Brenner et al. 2009; Spencer et al.
2009; Koenig et al. 2012; Tada et al. 2016). Within the cortical lamina, the 40 Hz ASSR sources
seem to be located principally in the thalamorecipient layer (layer 4) and layers 2/3 of the
supragranular cortex (Cardin et al. 2009; Javitt and Sweet 2015; Welle and Contreras 2016).
Deep layer 3 is the layer frequently associated with deficiency in the GABAergic cellular
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machinery important for gamma oscillatory function, as outlined above (Lewis et al. 2005).
Thus, 40 Hz ASSR deficits in patients may reflect the layer-specific alterations of inhibitory
function. Since gamma oscillations play an essential role in sensory and cognitive processing, 40
Hz ASSR presents an opportune biomarker specifically to examine cortical function relevant to
gamma frequency. Deficits in 40 Hz have been extensively shown to correlate with cognitive
dysfunction in schizophrenia (Light et al. 2006; Rass et al. 2012; Tada et al. 2016; Puvvada et al.
2018; Sun et al. 2018; Leonhardt et al. 2020). Furthermore, 40 Hz ASSR deficits have been
shown to correlate with the severity of schizophrenia symptoms in general (Zhou et al. 2018).
40 Hz ASSR is routinely used as a measure of hearing acuity in audiometry tests (Picton
2010). More recently, 40 Hz ASSR features have been used to develop an index to monitor the
depth of anesthesia during the induction phase, which is faster and more reliable than the
traditionally used EEG based bispectral (BIS) index (Haghighi et al. 2018). Similarly, a 40 Hz
ASSR based classification system has been reported to show a very high accuracy in identifying
sleep states (Khuwaja et al. 2015). As compared to other EEG measures (i.e., transient AER),
ASSR shows a better signal to noise ratio (S/N), making it a superior measure for circuit-level
function (Reijden et al. 2004; Ross et al. 2005; Yokota and Naruse 2015; Christensen et al. 2018;
Prado-Gutierrez et al. 2019). The 40 Hz ASSR has been reported to show a dose-dependent
attenuation in response to NMDA blockade, thus making it a relevant biomarker for drug
engagement studies involving NMDA transmission (Raza and Sivarao 2021). Schizophrenia
patients, and people at high risk, show a strong association of 40 Hz ASSR with treatment
outcomes (Molina et al. 2020; Grent- ‘t-Jong et al. 2021). In animal models, NMDAR
antagonist-induced deficits in 40 Hz ASSR mimic ASSR disruption seen in schizophrenia
patients (Sivarao et al. 2013; Thuné et al. 2016; Raza and Sivarao 2021). These findings point to
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encouraging predictive, construct and face validity features for testing 40 Hz ASSR in animal
models for studying NMDAR transmission.
Furthermore, 40 Hz ASSR is considered here as an endophenotype that reflects the
function of a discrete cortical circuit. LFP studies have shown layers 2/3 and 4 as the generators
of 40 Hz ASSR (Nakao and Nakazawa 2014; Javitt and Sweet 2015; Funk et al. 2020). These are
the regions associated with the generation of evoked gamma oscillations (Cardin et al. 2009;
Welle and Contreras 2016). The superficial cortical layers also play an essential role in sensory
processing (Quiquempoix et al. 2018) and cognitive function (e.g., working memory), processes
affected in schizophrenia. Moreover, cortical layers 2/3 have centrifugal projections, which play
an important role in integrating sensory information across different brain regions (Yamashita et
al. 2018). Thus, 40 Hz ASSR can be used as a biomarker to probe the structural and functional
integrity of superficial cortical layers associated with gamma oscillations.

Specific Aims
Schizophrenia is a severely debilitating mental illness affecting millions worldwide.
Current medications are at best only partially effective. Yet, there has been a scale back in the
pharma industry’s investment in developing new treatments, in part due to a lack of reliable and
disease-relevant biomarkers that can guide drug development (Weickert et al. 2013). Functional
markers are required for preclinical lead selection and to demonstrate target engagement. In
early-stage clinical drug development, biomarkers are critical for dose selection, proof of concept
evaluation and patient stratification. Absence of such process goal posts makes drug
development risky and discourages investment in psychiatric drug development.

44

Cutting across species, neural networks in the brain synchronize to discrete sounds such
as a brief tone or a rhythmic click train. The ensuing oscillatory activity can be captured in real
time using the technique of electroencephalography (EEG). Cutting-edge signal processing
reveals robust synchrony measures that are highly relevant to sensory and cognitive information
processing (Koshiyama et al. 2021). For example, clicks delivered at gamma frequency (~40
Hz), called the 40 Hz ASSR, evoke neural oscillations with high signal to noise ratio (McFadden
et al. 2014). Gamma oscillations are a product of NMDA-mediated activation of the parvalbumin
(PV) containing GABAergic interneurons and their modulation of the pyramidal neuron firing,
particularly in the superficial layers of the cortex (Cardin et al. 2009; Sohal et al. 2009).
Interestingly, schizophrenia patients show consistent deficits in transient gamma as well as 40 Hz
ASSR (Kwon et al. 1999; Shin et al. 2011; Thuné et al. 2016), while postmortem studies have
identified reduced GABAergic and glutamatergic markers in these layers (Hashimoto et al. 2003;
Catts et al. 2016). In healthy human subjects as well as in rodents, acute pharmacological
blockade of NMDA receptors results in gamma oscillatory deficits (Sivarao et al. 2013; Curic et
al. 2019). Thus, pharmacological modulation of gamma oscillatory response constitutes a
potential cortical layer-specific translational biomarker.
Yet, several aspects of the rodent assay remain unknown, limiting its potential for use in
drug development studies. For example, inter subject variability in drug response is a significant
challenge in neuropsychiatric drug testing. While within subject crossover design is a way to
minimize this variability, it is predicated on the assay being stable over an extended period of
time, to complete the crossover. While 40 Hz ASSR is disrupted by NMDA antagonism, we do
not know if positive modulators of the NMDA receptor like D-serine would improve it.
Furthermore, while rodent literature suggests several sites on the cortical mantle that are suitable
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for 40 Hz ASSR, we do not know if these are distinct or redundant measures of synchrony or if
one is preferable over the other. Answering these and other questions will fortify the rodent
version of the 40 Hz ASSR as a reliable tool for psychiatric drug development.
Specific Aim 1a. Evaluate the psychometric performance of the rodent 40 Hz ASSR
assay and the transient gamma oscillations over an extended period and demonstrate its
suitability for crossover designs (addressed in Chapter 2). Aim 1b. Demonstrate responsivity of
the assay measures to acute NMDA receptor blockade (Chapter 2).
Specific Aim 2a. Compare psychometric stability of 40 Hz ASSR from two discrete
cortical regions, the temporal cortex, and the vertex (chapter 3). Aim 2b. Evaluate if the 40 Hz
ASSR sensitivity to pharmacological intervention is different between these two regions
(Chapter 3).
Specific Aim 3a. Using a range of doses, evaluate if D-serine, a co-agonist at NMDA
receptor, can augment the gamma oscillatory response (Chapter 4). Aim 3b. Evaluate the 40 Hz
ASSR responsivity to acute dosing with a typical and atypical antipsychotic drug (Chapter 4)
Expected outcomes. By establishing robust psychometric properties of the 40 Hz ASSR,
and by demonstrating bidirectional modulation by pharmacological manipulations, we will
reveal a reliable cross-species CNS assay for the drug development pipeline.
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Abstract
Rationale. Schizophrenia patients consistently show deficits in sensory-evoked broadband gamma
oscillations and click-evoked entrainment at 40 Hz, called the 40-Hz auditory steady-state response
(ASSR). Since such evoked oscillations depend on cortical N-methyl D-aspartic acid (NMDA)mediated network activity, they can serve as pharmacodynamic biomarkers in the preclinical and
clinical development of drug candidates engaging these circuits. However, there are few test-retest
reliability data in preclinical species, a prerequisite for within-subject testing paradigms.
Objective. We investigated the long-term psychometric stability of these measures in a rodent
model.
Methods. Female rats with chronic epidural implants were used to record tone- and 40 Hz clickevoked responses at multiple time points and across six sessions, spread over 3 weeks. We
assessed reliability using intraclass correlation coefficients (ICC). Separately, we used mixedeffects ANOVA to examine time and session effects. Individual subject variability was
determined using the coefficient of variation (CV). Lastly, to illustrate the importance of longterm measure stability for within-subject testing design, we used low to moderate doses of an
NMDA antagonist MK801 (0.025–0.15 mg/kg) to disrupt the evoked response.
Results. We found that 40-Hz ASSR showed good reliability (ICC=0.60–0.75), while the
reliability of tone-evoked gamma ranged from poor to good (0.33–0.67). We noted time but no
session effects. Subjects showed a lower variance for ASSR over tone-evoked gamma. Both
measures were dose-dependently attenuated by NMDA antagonism.
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Conclusion. Overall, while both evoked gamma measures use NMDA transmission, 40-Hz
ASSR showed superior psychometric properties of higher ICC and lower CV, relative to toneevoked gamma.
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Introduction
Schizophrenia is a disorder in which information processing is abnormal at multiple
levels, from distorted transmission to impaired perception (Javitt, 2009a, 2009b; Krishnan et al.,
2011; Silverstein and Keane, 2011). Sensory-evoked neural responses in patients tend to be
smaller and less synchronized across many paradigms (Javitt, 2009a; Luck et al., 2011; Rissling
and Light, 2010), suggesting an abnormal registration and/or processing. Specifically, discrete
auditory stimulus-evoked oscillations in the gamma frequency range (30–100 Hz) are
consistently abnormal in schizophrenia as well as in other neuropsychiatric conditions like
autism and bipolar disorder. The local interactions between parvalbumin-positive GABAergic
basket cells and pyramidal cells are important for the generation of gamma oscillations
(Gonzalez-Burgos and Lewis, 2008; Tiesinga and Sejnowski, 2009). Specifically, pyramidal
neuron feed-forward activation of the N-methyl D-aspartic acid (NMDA) receptors on the basket
cells and their feedback inhibition of the pyramidal cells is critical for the emergence of these
oscillations (Buzsáki and Wang, 2012; Cardin et al., 2009; Gonzalez-Burgos and Lewis, 2012).
Principally, two types of gamma oscillations are evoked by auditory stimuli like tones
and clicks. A transient burst of broadband gamma oscillatory activity (~ 30 to 100 Hz) that is
coincident with the auditory-evoked P1-N1-P2 potential (Javitt and Sweet, 2015; Ross et al.,
2010) is observed in response to a discrete tone or click stimulus. A second type of response,
called the auditory steady-state response (ASSR), is an electroencephalographic (EEG)
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entrainment reflecting the driving frequency of periodic auditory stimuli such as clicks or
amplitude-modulated tones, lasting as long as the train stimulus, and typically elicited at 40 Hz
(Brenner et al., 2009). Both these responses are deficient in not only schizophrenia patients but
also in individuals that are at high risk for the disease (Leicht et al., 2011, 2016; Oribe et al.,
2019; Perez et al., 2013), making them state and trait markers. Moreover, an attenuation in toneevoked gamma is frequently associated with cognitive and negative symptoms (Curic et al.,
2019; Leicht et al., 2015). Offering a window to view such observations, Koshiyama et al., using
structural equation modeling, established a framework through which “bottom-up” sensory
measures like 40-Hz ASSR can influence clinical outcomes (Koshiyama et al., 2021). Moreover,
evoked gamma output before a therapeutic intervention predicted the degree of improvement
post-intervention, indicating a prognostic potential for circuit-level gamma response (Molina et
al., 2020). Thus, gamma markers are emerging as versatile tools with growing applications in
neuropsychiatric therapeutics (Kozono et al., 2019; Light et al., 2020; Luck et al., 2011; Sivarao,
2015; Sivarao et al., 2016).
In psychiatric drug development, there is now a greater appreciation for how patient
heterogeneity leads to high odds ratios for many clinically efficacious drugs (Stroup et al., 2007).
Clinical trials that use “within-subject” designs tend to better control such heterogeneity over
“between-subject” designs (Salkind, 2010). Moreover, within-subject designs involving the socalled N=1 trials are emerging as a sensitive means for identifying the most effective treatment
for an individual patient, taking into account his or her unique genetic/epigenetic background
(Lauschke et al., 2019). Stable, objective, circuit-level biomarkers can de-risk or accelerate such
fledgling efforts, by demonstrating neurophysiological engagement and guiding dose selection.
In preclinical discovery too, biomarkers are critical to demonstrate circuit engagement and
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enable prioritization of lead molecules for further development. Here too, within-subject
crossover designs are more sensitive to pharmacological treatment, yielding typically better
effect sizes over between-subject designs and requiring smaller group sizes to demonstrate
treatment effect (Cleophas and De Vogel, 1998; Guo et al., 2013).
However, the use of biomarkers in within-subject design studies is predicated on their
temporal stability to support multiple levels of drug treatment lasting weeks, if not months.
Several recent studies have reported on the stability of 40-Hz ASSR measures in healthy human
subjects (McFadden et al., 2014) as well as in schizophrenia patients (Cervenka et al., 2013; Ip et
al. 2018; Legget et al., 2017; McFadden et al., 2014; Roach et al., 2019). Overwhelmingly
though, such reports are limited to testing either a couple of times within one session (e.g., Ip et
al) or only across a couple of discrete sessions (e.g., Cervenka et al., 2013; Legget et al., 2017;
McFadden et al., 2014). Yet, to demonstrate target engagement, within the context of a repeated
measures design testing several dose levels of an experimental drug, one needs to show not only
temporal reliability within each session (for time-course) but also across several sessions (to
accomodate cross-over treatments). However, to the best of our knowledge, such studies, clinical
or preclinical, are largely missing.
In the current study, we tested the stability of tone-evoked broadband gamma (30–100
Hz) and 40 Hz click train-evoked narrowband gamma (35–45 Hz) activity in a group of female
rats, in six sessions, spread over a 3-week period. We investigated the test-retest reliability using
the intraclass correlation coefficients (ICC) at five discrete time points within each session. To
rule out carryover effects of repeated testing, we used mixed-effects ANOVA, using test sessions
and time of testing as fixed effects and subjects as a random effect. To estimate the individual
subject variability, we calculated coefficients of variation (CV). Lastly, to illustrate the
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importance of stability to pharmacological testing, we used a repeated measures design to test
low to moderate doses of the high affinity, open NMDA channel blocker MK-801, to disrupt
evoked gamma oscillations.

Methods

General
The Institutional Animal Care and Use Committee of the East Tennessee State University
approved all experimental procedures involving animal subjects. Female Sprague Dawley rats
(6–8-week-old; 200–250 g) were obtained from Envigo (Indianapolis, IN) and group housed
until surgery, with free access to food and water.

Surgical
Surgeries were performed under isoflurane anesthesia (5% induction: ~2% maintenance,
in oxygen, 1 L/min). The head was secured in a stereotaxic frame, and core temperature was
maintained at 36±1 °C. Head was shaved and disinfected with alcohol and povidone-iodine
swabs. Bupivacaine (0.25 %, sc) was used for a local nerve block and ketoprofen (5 mg/kg, sc)
was used for perioperative analgesia. Atropine sulfate (0.05 mg/kg, sc) was given to limit
respiratory secretions. Skull was exposed through a midline incision, followed by blunt
dissection. A solution of 3% hydrogen peroxide was used to disinfect and dry the skull. An
aseptic drill bit was used to drill four burr holes into the skull, and epidural electrodes with
attached wires were screwed in, avoiding damage to underlying dura. Electrode coordinates were
as follows: frontal, 1 mm anterior to bregma and 1 mm lateral to midline; vertex, 4.5 mm caudal
to bregma and 1 mm lateral to midline; reference, 2 mm caudal to lambda and 2 mm lateral (left
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side); and ground, 2 mm caudal to lambda and 2 mm lateral (right side). Dental cement slurry
was poured over the electrodes and allowed to set. Electrode wires were soldered to the
recording head mount (Pinnacle Technology, Lawrence, KS). For EMG, two wires from the head
mount were sutured to the nuchal muscle (however, EMG data was not used in this study). The
area was covered with a second layer of dental cement and, after curing, was closed using silk
sutures. Rats were allowed to recover from surgery for at least 10 days and were later handled
and acclimated extensively to the recording set up before use.

EEG Recording
Rats were placed in Plexiglas cylinders (Pinnacle Technology, Lawrence, KS) equipped
with a video camera and a house speaker (DROK, B00LSEVA8I). They were tethered to the
setup through a shielded preamplifier cable and a commutator for continuous EEG recording
while permitting free access to explore within the chamber. The acquisition system (CED Power
1401; Cambridge Electronics Design (CED), Cambridge, UK) produced the auditory stimuli, as
well as acquired the EEG (Signal v7); data were acquired as 5-s sequential sweeps (1 KHz
sample rate). A tone stimulus (1 KHz, 2mV sinusoidal wave, 50-ms duration, 65 dB) was
presented 1 s after sweep initiation. A click train (5 mV monophasic, 1-ms long square waves,
20/0.5 s, ~ 65 dB) was presented 2 s following the tone stimulus. Interval between the end of the
click train and the beginning of the next tone was 2.5 s. Evoked responses were averaged from ~
75 consecutive trials. For the ICC study, data were acquired at 0 (i.e., immediately after the
animals were tethered), 30, 60, 90 and 120 min. The 0 min time point was omitted in the
pharmacology study. Six sessions, each separated by at least 3 days, were used for the reliability
study, whereas pharmacology study was carried out in four sessions (vehicle plus 3 dose levels
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of MK801). EEG data discussed here were obtained from the vertex electrode. A schematic of
the two studies (A and C) along with the Latin square (B) used in the pharmacology study are
shown in fig. 2.1.

EEG Data Analysis
While all EEG data were evaluated for movement artifacts, very few frames (<3%)
needed exclusion. Animal movement by and large did not affect the EEG. However, occasional
chewing-related movements were noted and excluded if such movements were coincident with
the auditory response. Thus, ~75 artifact-free frames were averaged per subject per time point, to
generate an evoked response. Evoked response was band-pass filtered (30–100 Hz for tone and
35–45 Hz for the click train, using a second order Hanning infinite impulse response (IIR) filter;
Signal v7). Root mean square (RMS) amplitudes were computed for tone-evoked (0–150 ms
from onset) and ASSR (0-500 ms from onset), for each subject, at each time point. These were
further averaged to summarize group responses.

Pharmacology
MK801 maleate (MW 337.4 g/mol) was obtained from Sigma-Aldrich. Free base mass
was used to make 0.15 mg/ml stock solution, and this was diluted to make 0.025 and 0.05 mg/ml.
MK801 doses were chosen to capture a wide range of NMDA channel occupancy (Fernandes et
al. 2015). Rats were given intraperitoneal (IP) injection of either vehicle or MK-801 (1 ml/kg,
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Figure 2.1. Schematic representations of the study design for the test-retest reliability (A), the Latin square treatment (B), and the
MK-801 pharmacology study (C).
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volume) at the start of experiment in a Latin-square design (fig. 2.1-B) and were then placed in
the recording chamber. At least a 3-day period was allowed for washout, between treatments.
Animals were monitored for carryover effects and weight fluctuations, but none were noted.

Statistics
Since a key goal of this work was to evaluate the suitability of evoked gamma
oscillations as biomarkers in a repeated measures design, we wanted to know if there were any
systemic effects of repeated testing. For this, we used a mixed-effects ANOVA (restricted
maximum likelihood estimation as implemented in GraphPad Prism v8.4.3). Time of testing
within a session was designated as a row factor, while multiple sessions were designated as a
column factor. Data normality was assessed using quantile-quantile (q-q) plots. Sphericity was
not assumed, and Greenhouse-Geisser correction was used. Where appropriate, Dunnett’s tests
were used to evaluate within session significance, using time-zero response as a comparator. For
pharmacology studies, vehicle group at each time point was used as the comparator.
Reliability was measured by calculating the intraclass correlation coefficients (ICC).
Defined as the ratio of subject variance to total (subject + error) variance, ICC assesses the
reliability of an evoked response by comparing the between-measures variability of each subject
to the total variation across all measures and all subjects (Koo and Li 2016; Tan et al. 2015).
Unlike Pearson’s correlation coefficient, which detects the linear association between two
measures, irrespective of their absolute values, ICCs reflect the agreement of a subject’s evoked
power from one session to another, accounting for the variances (Tan et al., 2015).
There are many types of ICC reported in the literature. We implemented the two -way
mixed-effects, absolute agreement, and single measurement formula, as discussed by Koo and Li
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(2016). ICC estimates along with their 95% confidence intervals were calculated using SPSS
statistical package (SPSS v26, Chicago, IL). We used a qualitative interpretation of the ICC
values as reported recently by Ip et al., (2018). Thus, an ICC less than 0.39 was considered to be
an indicator of poor test-retest reliability, while ICC ranges between 0.40–0.59, 0.60–0.75 and
0.76, and above were considered respectively to be fair, good, or excellent (Ip et al., 2018).

Results
Auditory stimuli comprising of tone and click trains evoked robust broadband gamma
and steady-state entrainment respectively, in all subjects. An overlay in fig. 2.2. shows the grand
averaged RMS amplitude data from six sessions, corresponding to discrete time points (0 to 120
min) from a group of 12 rats; panel A summarizes tone-evoked gamma band activity while panel
B shows the ASSR. Individual subject averages for each session for both measures are shown in
a supplementary figure (fig. 1 supp).
For tone-evoked γ, a linear Q-Q plot confirmed normal distribution (data not shown).
Mixed-effects ANOVA showed a highly significant effect of time on group means (p<0.0001; F
(2.580, 28.38) = 13.91; epsilon = 0.6449). However, no significant session effect (p=0.2195; F
(2.458, 27.04) = 1.590; epsilon = 0.4917) or interaction of time × session (p=0.1896; F (5.319,
55.85) = 1.538; epsilon = 0.2659) were noted. Examining the mean response across time
indicated a pattern of smaller average responses at time zero relative to other times points (fig.
2.2-A). Confirming this, post hoc analysis showed that the time-zero response was smaller than
several other time points within each session (p<0.05; Dunnett’s tests). Such differences were
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Figure 2.2. Overlay of the RMS amplitude measures of 1 KHz tone-evoked broadband gamma (30–100 Hz; A) and 40 Hz click-evoked
narrowband steady-state response (35–45 Hz; B) at 0–120-min time points across 6 discrete sessions, spread over a 3-week period. Data
were from a group of 12 rats.
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noted in session 1 (p<0.05; 0 min vs. 30, 60, and 90 min), session 2 (0 min vs. 30, 60, 90, and
120 min), session 3 (0 min vs. 30, 60, and 120 min), and session 5 (0 min vs. 120 min).
The 40-Hz ASSR data too were normally distributed, based on a linear Q-Q plot (not
shown). As with the tone-evoked gamma, mixed-effects analysis of 40-Hz ASSR showed a
highly significant effect of time (p=0.0001; F (3.1, 34.10) = 8.956; epsilon = 0.7751) but no
session effect (p=0.3021; F (2.5, 27.5) = 1.268; epsilon = 0.5) or interaction of time × session
(p=0.6067; F (3.916, 41.12) = 0.6802; epsilon = 0.1958). As with transient gamma, mean ASSR
at time zero tended to be smaller than responses at other time points (fig. 2.2-B). Within session
Dunnett’s tests revealed following contrasts to be significant (p<0.05): session 2 (0 min vs. 120
min), session 3 (0 min vs 60 min), session 4 (0 min vs. 60 min and 120 min), session 5 (0 min vs.
60 and 120 min), and session 6 (0 min vs. 60 and 120 min).
We next calculated the ICCs for each time point across sessions using a two-way mixedeffects model using single measurement, absolute agreement criteria as discussed elsewhere
(Koo and Li 2016). The ICCs along with their 95% CIs, at designated time points and across 6
sessions, are shown in Table 1. Tone-evoked gamma, with the exception of one time point,
showed an ICC that had a fair measure of reliability (0.33–0.67). On the other hand, ICC for 40Hz ASSR showed good (0.60–0.75) reliability. Although we did not do a pair-wise statistical
comparison between the two, it is apparent from the data summarized in Table 1 that for the
same group of subjects, in each instance, 40-Hz ASSR had higher ICCs compared to toneevoked gamma.
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Table 2.1. Intraclass Correlation Coefficients (ICC) Across Time Points From Six Sessions. ICC
were calculated using a two-way mixed-effects model, single measurement, and absolute
agreement criteria (Koo and Li, 2016).

Since the same group of 12 rats was repeatedly tested ~30 times, spread over 3 weeks, we
had an opportunity to calculate % coefficient of variation (CV) as a measure of individual
subject’s response precision. Mean CV for tone-evoked gamma was 31.6%. In contrast, the mean
CV for 40-Hz ASSR was markedly lower at 20.9. Fig. 2.3 summarizes these data as a violin plot,
highlighting the difference between the two measures (p=0.0001; paired t-test).
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Figure 2.3. Summary of coefficient of variations (CV) of tone-evoked and 40 Hz click trainevoked responses from a group of 12 rats. Individual subject CVs are indicated within the violin
plots. Significant difference between the two groups is indicated by asterisks (p = 0.0001; paired
t-test).

In the second part of the study, we illustrated the utility of temporal stability of these
measures by carrying out a dose-response with the NMDA channel blocker MK801, using a
repeated measures design. We chose to omit testing at time zero but tested at other time points
(30–120 min) post-dose. The dose of 0.15 mg/kg dose of MK-801 induced hyperactivity,
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Figure 2.4. A compilation of grand average of narrow band gamma (35–45 Hz) activity in
response to auditory tone (1 KHz) and 40-Hz click stimuli, 120 min after vehicle or MK801
(0.025, 0.05, or 0.15 mg/kg, ip) treatment. Data represents a grand average from 10 subjects.
Note that the actual tone-evoked data were computed over a broadband of 30–100 Hz.
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circumambulation along with stereotypic head movements that persisted for 3–4 h post-injection.
However, no behavioral changes were noted at 0.025 or 0.05 mg/kg doses.
MK801 disrupted tone-evoked gamma in a highly dose-dependent and time-dependent
manner. Fig. 2.5 summarizes the grand averaged evoked responses for all treatments, across all
subjects, 60 min post-treatment. Fig. 2.5 (top panel) summarizes tone-evoked gamma after
vehicle or MK801 treatments, along with individual RMS values. Normal distribution of the data
was first ascertained through a Q-Q plot (not shown). Mixed-effects ANOVA showed a robust
treatment effect (p<0.0001; F (1.574, 14.16) = 25.98; epsilon = 0.5246) but no time effect (p=
0.4709; F (2.280, 20.25) = 0.8149; epsilon = 0.7600) or time × treatment interaction (p=0.2007;
F (2.245, 20.21) = 1.728; epsilon = 0.2495). Post hoc comparisons using Dunnett’s test showed
that only 0.05 and 0.15 mg/kg doses of MK801 significantly (p<0.05) attenuated tone-evoked
gamma at multiple time-points, relative to vehicle treatment.
ASSR data too were normally distributed, based on a Q-Q plot (not shown). The 40-Hz
ASSR responses from each subject along with group mean for each treatment condition are
summarized in fig. 2.5, bottom panel. MK801 dose- and time-dependently disrupted 40 Hz trainevoked gamma. Robust treatment effect was noted (p<0.0001; F (1.884, 16.95) = 31.39; epsilon
= 0.6279). However, neither time (p=0.4365; F (2.679, 24.11) = 0.9208; epsilon = 0.8930) nor
time × treatment (p=0.5328; F (3.800, 34.20) = 0.7922; epsilon = 0.4222) were significant. Post
hoc testing showed that all three doses were effective (p<0.05) at one or more time points, in
reducing 40-Hz ASSR response, using vehicle treatment as a comparator.
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Figure 2.5. Compilation of RMS data of tone-evoked gamma (top panel) and 40-Hz ASSR
(bottom panel) in a group of rats treated with vehicle or MK801 (0.025, 0.05, or 0.15 mg/kg sc),
at discrete time points (30, 60, 90, and 120 min). Significant differences between vehicle
treatment and MK801 treatment are indicated by asterisks (*/**/***indicates p<0.05/0.01/0.001;
Dunnett’s post hoc tests). Data are from a group of 10 rats.
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Discussion
Circuit-based functional biomarkers are critical for early phase drug development; for
prioritizing lead candidates in preclinical species and in the clinic for dose selection, proof of
concept, and patient stratification (Light et al., 2020; Spellman and Gordon, 2015). While there
are several recent clinical reports that show test-retest reliability for tone- and train-evoked
gamma oscillations (Cervenka et al., 2013; Legget et al. 2017; McFadden et al., 2014; Tan et al.,
2015), such findings only infrequently extend beyond a few test sessions (Ip et al., 2018; Roach
et al., 2019). To date, complementary reliability studies of evoked gamma in preclinical species
are unavailable. Thus, our current report addresses an important translational knowledge gap by
establishing test-retest reliability of tone- and 40 Hz-train-evoked gamma oscillations across
multiple sessions and time points, spread over a 3-week period.
Since our interest is in using these EEG measures for pharmacological testing using
repeated measures design, we evaluated time and session effects (fixed variables) with subjects
modeled as random effect, using a mixed-effects analysis. We found a robust time effect with
time-zero response tending to be smaller in comparison to all other time points. Although rats
were extensively acclimated, transfer from home cage to the recording chamber triggered an
arousal response that may have affected the initial time point (Griskova-Bulanova et al., 2011;
Griskova et al., 2007). Indeed, this period is often coincident with increased exploration of the
recording chamber and whisking that dwindles over the following 30-min period (Drake et al.
1991).
We used female rats but did not monitor the estrous cycle during the study. While there
was some session-to-session variability, it was not significant at the group level. It is however
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not possible to conclude that estrous cycling did not affect the measures in question. This is
something that needs studying in future along with determining psychometric reliability in
males. There was no effect of session or session × time on the EEG measures. Since exploratory
analysis suggested that response at time zero drove the time effect, we decided to omit sampling
at time zero in the pharmacological study, to simplify data interpretation. This appeared to have
removed time as a significant factor.
Our results indicate that while tone-evoked gamma and 40 Hz train-evoked gamma
responses show acceptable reliability, 40-Hz ASSR is superior. Thus, at the group level, 40-Hz
ASSR had a lower re-test related variance, compared to tone-evoked gamma. Since the same
group of rats were repeatedly tested, we had an opportunity to evaluate if for a given subject, one
measure evoked a more consistent response. We found that across ~30 test occasions conducted
with the same 12 subjects, ASSR showed a consistently smaller CV than tone-evoked gamma,
suggesting that the ASSR measure is less variable.
For testing the effect of the open channel blocker MK801 on gamma oscillations, we
chose to include a range of doses that spanned an estimated occupancy of ~20 to 70% of the
NMDA receptor pool (Fernandes et al., 2015). MK801 showed robust suppression of both the
evoked measures at 0.05 mg/kg and 0.15 mg/kg doses. However, 0.025 mg/kg of MK801 was
effective only against 40-Hz ASSR. The lower variance in the ASSR may have helped reveal the
low dose effect.
In summary, we report the test-retest reliability of two frequently used response markers
of sensory cortical circuit function that lend themselves for use as pharmacodynamic biomarkers.
While both display acceptable psychometric properties for use in preclinical drug discovery and
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are sensitive to disruption of NMDA neurotransmission, particularly in the context of within
subject repeated measures, 40-Hz ASSR has a quantitative edge over tone-evoked gamma.
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CHAPTER 3. THE 40 HZ ASSR RECORDED FROM THE VERTEX AND THE TEMPORAL
REGIONS REPRESENT DISTINCT AND NOT REDUNDANT RESPONSES
Abstract
Rationale. Clinical literature indicates multiple cortical sources for the ASSR (Tada et al., 2019;
Farahani et al., 2017). There have been at least eight cortical and subcortical primary generators
of ASSR reported in previous studies (e.g., Farahani et al., 2019, 2021). However, recordings
from the temporal region (targeting the primary auditory cortex) show the highest ASSR
amplitude. Preclinically, epidural recording electrode positions are not standardized. ASSRs
have been previously recorded from electrodes placed frontally, temporally or from the parietal
cortex (Leishman et al., 2015; Sivarao et al., 2016; Kozono et al., 2019; Wang et al., 2020).
Since the general practice has been to use one or the other but not all at the same time, it is
unclear if any one position is more reliable than the others or if they all yield comparable results.
To date, there have not been many studies that have made a head-to-head comparison between
discrete regions to determine if: (1) one region is better than others or they have comparable
reliability and (2) if they have comparable pharmacological sensitivity to test compounds.
Objective. We investigated the long-term stability and pharmacological sensitivity of 40 Hz
ASSR recorded from vertex and temporal regions.
Methods. In the current study, we simultaneously recorded 40 Hz ASSR from the vertex and
temporal electrodes in freely moving female rats, in four different sessions spanning a period of
two weeks. Then, we evaluated the test-retest reliability of the measure through an intraclass
correlation coefficient (ICC). Furthermore, we tested the effect of an open-channel NMDA
receptor blocker MK-801 (0.025-0.1 mg/kg, SC) on the 40 Hz ASSR recorded from these two
electrodes.
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Results. We found that the 40 Hz ASSR obtained from the vertex region (overlying the
retrosplenial cortex, a region implicated in episodic memory, navigation, and planning), while
showing a smaller amplitude, had a good test-retest reliability, whereas the temporal 40 Hz
ASSR, despite having a large amplitude and strong intertrial coherence, showed a relatively poor
test-retest reliability. In the pharmacology study, vertex showed a strong dose-dependent
reduction in 40 Hz ASSR in response to MK801, as demonstrated previously (Raza and Sivarao
2021). However, temporal 40 Hz ASSR did not show a comparable disruption. In a follow up
study, we evaluated if a 3-fold higher dose of MK801 (0.3 mg/kg) would engender a reduction
on the temporal cortex derived 40 Hz ASSR. Indeed, this higher dose of MK801 did strongly
disrupt the temporal response.
Conclusion. These results show marked regional differences in the properties of the 40 Hz ASSR.
Our results also highlight the observation that an identical stimulus paradigm can yield circuit
responses with differing psychometric properties. Moreover, it is critical to understand these
differences before pursuing pharmacology studies in preclinical species, especially when repeated
measures design, rather than parallel groups is employed. Our results further indicate that the
vertex region which involves the retosplenial cortex, a region that is increasingly recognized to be
involved in a range of cognitive functions like learning, spatial navigation, and episodic memory
(Vann et al., 2009; Stacho and Manahan-Vaughan, 2022), is highly sensitive to NMDA blockade.
On the other hand, the 40 Hz ASSR response from the temporal cortex seems less sensitive to
NMDAR blockade.
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Introduction
Auditory steady-state response (ASSR) is an entrained response of cortical neural
populations synchronized to short trains of auditory click stimuli (Brenner et al., 2009). The
evoked response recorded through EEG or MEG shows neural activity which is time and phaselocked to the driving stimulus frequency. ASSR has utility in audiometry and for monitoring the
state of arousal under anesthesia (Draganova et al., 2008; Borck et al., 2011; Haghighi et al.,
2018). ASSR, especially at gamma frequency (~ 40 Hz), is disrupted in schizophrenia (Thuné et
al., 2016; Brenner et al., 2009), as well as in other psychiatric conditions such as bipolar
depression (Rass et al., 2010) and autism (Seymour et al., 2020).
Due to the translational replicability of EEG across mammalian species, EEG-based
biomarkers, in principle, provide an excellent tool to probe not only circuit function but also test
promising therapeutic approaches for psychiatric illnesses. Studies have shown robust deficits in
ASSR measures like evoked power and inter-trial coherence in schizophrenia patients (Brenner
et al., 2009; Thuné et al., 2016). This has led to the development of pre-clinical animal models
mimicking 40 Hz ASSR deficits as seen in human psychiatric subjects. Pharmacological
manipulation in the form of acute dosing with NMDA receptor (NMDAR) antagonists like PCP
(Leishman et al., 2015), Ketamine (Plourde et al., 1997; Sivarao et al., 2016), or MK-801 (Wang
et al., 2020; Sivarao et al., 2013) disrupt 40 Hz ASSR synchrony. Moreover, genetic ablation of
the NR1 subunit of NMDAR complex also demonstrated a selective entrainment deficit at
gamma frequencies (Carlén et al., 2012; Nakai and Nakazawa 2014). Thus, 40 Hz ASSR has
been proposed as a pharmacodynamic biomarker to investigate NMDAR-associated
pathophysiology in schizophrenia and facilitate NMDAR-focused antipsychotic development
(Sivarao, 2015).
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Modeling schizophrenia, an essentially human malady in animals, poses a formidable
challenge (Weickert et al., 2013). The use of circuit-based markers like 40 Hz ASSR as an
intermediate phenotype may prove to be a more translatable and therefore viable proposition. At
present, however, there is no uniformity of protocols for ASSR recording in preclinical species.
Different studies have reported ASSR results by recording EEG from different cortical regions
(Conti et al., 1999; Sivarao et al., 2016; Kozono et al., 2019; Wang et al., 2018). Moreover, there
is only one study that we are aware of, that compared how a particular intervention (anesthesia)
affected the same measure recorded concurrently from two or more anatomically discrete regions
(Wang et al., 2018). This is an important question as we know that there are multiple generators
in the brain for the 40 Hz ASSR (Farahani et al., 2019, 2021). However, it is unclear if they
represent redundant or independent processes. Where there are multiple sources, it remains to be
established if each of them are equally reliable or if some are more stable than others. This is an
especially pertinent question when crossover designs are used to limit individual subject
variability, as the same subject gets tested on different occasions, over a significant period. At
the same time, it also remains to be established if such multiple sources are equally sensitive to
pharmacological intervention.
In the current study, we implanted female Sprague Dawley (SD) rats with temporal and
vertex electrodes for simultaneous recording of 40 Hz ASSR, while unrestrained. These two sites
ostensibly represent electrical activity from the underlying regions, the primary auditory cortex,
and the retrosplenial cortex, respectively. In the first experiment, we compared not only the
stimulus-evoked responses but also their test-retest reliability across vertex and temporal
electrodes. Furthermore, we compared the effect of the non-selective NMDAR inhibitor MK-801
on 40 Hz ASSR from the vertex and temporal recordings in a cross-over study design. We tested
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three different doses of MK-801 (i.e., 0.025, 0.05, and 0.1 mg/kg), which show a wide range of
NMDAR occupancy to compare the sensitivity of 40 Hz ASSR recorded form vertex and
temporal regions to NMDAR inhibition. The current study provides important insight into the
recording-site specific test-retest reliability, and sensitivity of 40 Hz ASSR to NMDAR
inhibition. Studies like this are a crucial step in establishing 40 Hz ASSR as a translational
biomarker in psychiatric research.

Methods

General
The Institutional Animal Care and use Committee of the East Tennessee State University
approved all experimental procedures involving animal subjects. Female Sprague Dawley rats
(6-8-week-old; 200-250 g) were obtained from Envigo (Indianapolis, IN) and group housed until
surgery, with free access to food and water.

Surgery
Each rat was implanted with epidermal electrodes through stereotaxic surgery. Isoflurane
(5%) was used to induce anesthesia and the head was fixed in the stereotaxis frame. Anesthesia
was maintained with 2% isoflurane during surgery. Aseptic techniques were strictly followed to
avoid contamination and infection. The surgery area was cleaned with alcohol and iodine swabs.
Bupivacaine was infiltrated under the skin above the skull as field anesthesia. Meloxicam (1
mg/kg, sc) was given as part of perioperative analgesia. The skull was exposed through a single
midline incision on the scalp. A blunt instrument was used to scrape the tissue off the skull and
hydrogen peroxide (H2O2) was used to disinfect and dry the exposed bone. A 4 mm exposed
77

area was created by bisecting and removing the temporalis muscle to expose the temporal ridge
as described previously (Kozono, et. al., 2019). Any bleeding was stopped though a cauterizer. A
handheld drill bit was used to drill four holes in the skull at the following coordinates: from
bregma, -4mm AP/ -1mm ML (vertex electrode; overlying the retrosplenial cortex); from
bregma, -4 mm AP, 7.5 lateral to the sagittal suture, and -4 mm DV (temporal electrode;
overlying the primary auditory cortex); from lambda, -2 mm AP, ±2 mm bilaterally (ground and
reference electrodes, overlying the cerebellum). The electrode positions are marked in fig. 3.1-A.
The stainless-steel electrodes with attached wires were gently screwed into the holes without
causing any damage to dura mater. Dental cement slurry was used to cover the electrodes and the
free ends of the electrode wires were fused to the EEG head mount through a solder. All the
exposed wires were covered with another layer of dental cement. Nylon sutures were used to
stitch the area and the wound was covered with a topical antibiotic ointment. A single tablet of
Baytril (2mg/tab) was given for 7 days post-surgery to prevent postoperative infection.

Experimental Protocol
40 Hz ASSR recordings were carried out as described previously (Raza and Sivarao,
2021). Briefly, each rat was placed in the recording chamber and the headpiece was connected to
the recording setup through a preamplifier cable. Auditory stimuli were presented, and EEG was
simultaneously recorded through an acquisition device (CED Micro 1401-3; Cambridge
Electronics Design (CED), Cambridge, UK)). Signal software was used to acquire EEG data at a
sampling rate of 1000 Hz. Auditory stimuli consisted of a 1-second long 40 Hz click train
(square wave, 65dB intensity, and 50 msec click duration) in a 3.5 second trial, which was
repeated in rapid succession, 75 times. Each recording session started after a 10-minute
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acclimation period. For the test-retest reliability study, rats were recorded for a 120-minute
period, at 30 minutes intervals (i.e., 30, 60, 90 and 120 minutes) in a single session. Recordings
were repeated for four sessions spanning a period of two weeks with a three-day interval
between each recording session. In the MK-801 pharmacology study, a crossover study design
was followed, where each rat received a different treatment as per a Latin square design, on
different recording sessions. The washout period between sessions was at least 3 days and the
study was completed in two weeks. MK-801 (as maleate salt from Sigma-Aldrich) was
dissolved in 0.9% saline to prepare a stock solution of 0.1 mg/ml (based on free base mass),
which was aliquoted and kept at -200C. Serial dilutions were made before dosing to appropriate
concentrations.

EEG Data Analysis
The acquired EEG data was screened for chewing associated artifacts and only artifact
free trials were selected for analysis (~70). Time-frequency analysis (TFA) was performed in the
EMSE data editor software v5.6.1 (Cortech solutions, Wilmington, NC). Signal software v7.1
was used to first record the raw data, which were then exported as text files. The text files were
then imported into EMSE v5.X software (Cortech Solutions Inc., Wilmington, NC). Morlet
transformation was applied for TFA to obtain evoked power and inter-trial phase coherence
(ITC). TFA involves convolution of the Morlet wavelet with EEG waveform to obtain timevarying wavelet transform coefficients (complex valued). Information about the amplitude (M)
and phase (φ) are extracted from these complex valued coefficients (Morales and Bowers, 2022).
ITC value represent trial-to-trial phase consistency, while evoked power is the measure of
averaged 40 Hz ASSR power. Both ITC and evoked power measure 40 Hz ASSR signal, which
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is time-locked to stimulus onset (Brian J. Roach and Mathalon, 2008). Peak and area
measurements of 40 Hz ASSR for ITC and evoked power were obtained to perform statistical

(A)

(B)

Animals placed in Animals connected
the recording
to the recording
chamber
setup

10 minutes for
acclimation

Animals removed

ASSR recording at 30, 60, 90 and 120 minutes
post-connection

Repeated after > 3 days
Four sessions

Animals placed in
the recording
chamber

Animals connected
to the recording
setup
MK-801
injection

10 minutes for 5 minutes
acclimation
rest

Animals removed

ASSR recording at 30, 60, 90 and 120 minutes
post-MK-801 injection

Repeated after > 3 days

80

Figure 3.1. Schematic representations of the electrode placement (A), and study design for testretest reliability and pharmacology studies (B). (sc) indicates subcutaneous dosing.

analysis. TFA was also performed on the concatenated data from each group to obtain summary
results for representation.

Statistical Analysis
The key objective for the current study was to determine the suitability of vertex and
temporal regions for 40 Hz ASSR recording in a repeated measures design. We first analyzed the
effect of brain regions on 40 Hz ASSR recording. Then we examined the systematic effect of
repeated testing on 40 Hz ASSR recorded from vertex and temporal regions simultaneously. We
also compared the pharmacological effects of MK-801 treatment on vertex and temporal 40 Hz
ASSR. We used a mixed-effects ANOVA (restricted maximum likelihood estimation as applied
in GraphPad Prism v9.3.1 software) to determine the effect of brain region, repeated testing, and
MK-801 treatment on 40 Hz ASSR. Time of recording was always selected as a row factor,
while brain region, recording sessions, or pharmacological treatment were selected as a column
factor. Data normality was ensured through Quantile-quantile (q-q) plot. In case the data were
non-linear, we log transformed the data first to confirm linearity and then, parametric statistics
were applied. Greenhouse-Geisser correction was implemented without assuming sphericity.
Where appropriate, Bonferroni or Dunnett’s post hoc analysis were used to measure between
regions, sessions or treatment significance. In reliability study, session 1 was selected as
comparator to measure between sessions significance, while 30 minutes timepoint was selected
as comparator to measures within session significance, In the MK-801 pharmacology study,
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vehicle group was selected as a comparator. Data are represented as group mean along with the
SEM.
Test-retest reliability of the 40 Hz recording from the vertex and temporal electrodes was
measured through the intra-class correlation coefficient. We chose mixed-effects, absolute
agreement, and single measurement model for consistency with the previous studies as discussed
previously (Koo and Li, 2016; Raza and Sivarao, 2021). Test-retest reliability between 4 sessions
was measured for each of the four time-intervals (30-120 min). Sessions were selected as column
factor and rats were selected as row factors for each time-intervals. SPSS statistical package
(SPSS v26, Chicago, IL) was used to estimate ICC along with 95% confidence interval. ICC
values were categorized as poor (<0.39), fair (0.40-0.59), good (0.60-0.75), and excellent (>0.76)
(Ip et al., 2018; Raza and Sivarao, 2021). The variability of 40 Hz ASSR was measured through
% coefficient of variation (% CV).

Results

Temporal Recordings Showed A Significantly Higher 40 Hz ASSR As Compared To Vertex
Clear evoked responses in the form of a large registration potential (P1-N1-P2) followed
by visible entrainment of the click stimuli were recorded from both vertex and the temporal
cortex. However, the recordings from the temporal cortex tended to be several fold larger than
the vertex response (fig. 3.2-A). Filtered and unfiltered grand average compilation of vertex and
temporal 40 Hz ASSR recordings are shown in fig. 3.2-A. Mixed-effects ANOVA with repeated
measures design showed a highly significant effect of recording sites on ITC (p<0.0001; F (1, 9)
= 80.40; epsilon = 1). However, there was no significant time effect (p=0.3319; F (2.065, 18.58)
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= 1.176; epsilon = 0.6883) or significant interaction between time and recording sites (p=0.1972;
F (1.762, 15.85) = 1.813; epsilon = 0.5872). Further post hoc analysis showed a significantly
higher 40 Hz ASSR ITC recorded from temporal region, as compared to vertex across at all time
points (p<0.01-p<0.0001)
Evoked power also showed a highly significant effect of recording sites (p<0.0001; F (1,
9) = 89.93; epsilon = 1). However, there was no significant time effect (p=0.5350; F (1.586,
14.27) = 0.5793; epsilon = 0.5287) or significant interaction between time and recording sites
(p=0.3619; F (2.010, 18.09) = 1.077; epsilon = 0.67). Multiple comparison revealed significantly
higher evoked power of temporal 40 Hz ASSR, relative to vertex 40 Hz ASSR (p<0.001(p<0.0001). Group mean summaries for ITC and evoked power of 40 Hz ASSR recorded from
vertex and temporal regions are summarized in fig. 3.2 (B and C).
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(A)

(B)

(C)

Figure 3.2. Comparison of 40 Hz ASSR recorded from vertex and temporal regions. A
compilation of grand average (n=12) of unfiltered and narrow-band filtered (35–45 Hz) 40 Hz
ASSR recorded from vertex and temporal regions (A) at 60 minutes time point. Time frequency
analysis (TFA) was performed to calculate ITC (A), and evoked power (B) for vertex and
temporal 40 Hz ASSR. The data represent group summaries from 12 rats, across 30, 60, 90, and
120 minutes from session 1. Significant differences between vertex and temporal 40 Hz ASSR
are indicated by asterisks (**/***/****indicates p<0.01/p<0.001/0.0001; Bonferroni post hoc
test).
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40 Hz ASSR Recording From Vertex Showed Good Test-Retest Reliability, While Reliability Of
Temporal 40 Hz ASSR Was Poor
In order for 40 Hz ASSR to be a translational biomarker, it must have good reliability.
We tested the consistency of 40 Hz ASSR evoked power over a period of two weeks spanning
four sessions. We performed repeated measures ANOVA on the evoked power data obtained
from vertex and temporal recording sites to calculate between sessions and within session
differences. Evoked power for vertex 40 Hz ASSR showed a significant session effect (p<0.05; F
(2.689, 26.89) = 4.726; epsilon = 0.8963) on group means. However, there was no effect of time
(p=0.6533; F (1.933, 19.33) = 0.4247; epsilon = 0.6445) or time x session interaction (p=0.4024;
F (4.194, 41.94) = 1.035; epsilon = 0.4660). Dunnett’s post hoc analysis, with session 1 as a
comparator showed a significant difference with session 4 (P<0.05) at only 30 minutes.
Then, we then analyzed the systematic effect of repeated testing on temporal 40 Hz
ASSR evoked power. Repeated measures ANOVA showed a highly significant time effect
(p<0.001; F (2.46, 24.59) = 8.60; epsilon = 0.82) but no session effect (p>0.05; F (1.99, 19.92) =
2.23; epsilon = 0.66) or time x session interaction (p>0.05; F (3.89, 38.86) = 2.25; epsilon =
0.43). Post hoc multiple comparisons (Dunnett’s) showed that group means at 30 minutes timepoint were significantly different from 90 and 120 minutes in session 1 (p<0.05), and from 90
(p<0.05), 60 and 120 (p<0.01) minutes in session 2, 3 and 4, respectively.
Intraclass correlation coefficient (ICC) was measured to calculate reliability of 40 Hz
ASSR recordings from the vertex and temporal regions. Vertex showed good test-retest
reliability (ICC = 0.6-0.75) except at 30 minutes (ICC = 0.40-0.59). Whereas the test-retest
reliability of temporal 40 Hz ASSR was poor (ICC = 0-0.14) across all sessions for all time
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points. The ICC values for each time point across 4 sessions, along with their 95% CIs, are
shown in Table 1. We did not perform pairwise comparisons of ICCs for vertex and temporal 40
Hz ASSR, as the difference in ICCs between the two groups is noticeable from table 1.

Table 3.1. ICC For 40 Hz ASSR Evoked Power From Vertex And Temporal Recording. ICC
values for four sessions across time points (i.e., 30, 60, 90 and 120 minutes) were calculated
using a two-way mixed-effects model, single measurement, and absolute agreement criteria (Koo
and Li 2016). The data are from a group of 12 rats.

Time
30
60
90
120

ICC
0.5
0.67
0.67
0.65

Vertex
95% CI
0.21-0.79
0.40-0.88
0.40-0.88
0.38-0.87

Temporal
ICC
95% CI
0
0-0.34
0.14 0-0.51
0.07 0-0.44
0.06 0-0.41

We also performed Pearson‘s correlation analysis for each time points between session 1 and the
rest of the sessions (i.e., sessions 2-4). Vertex recordings of 40 Hz ASSR showed a moderate
correlation across sessions (r = 0.53-0.87), whereas there was no correlation across sessions for
temporal recordings. Table 3.2 shows Pearson’s correlation coefficient (r) values for vertex and
temporal 40 Hz ASSR recordings.
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Table 3.2. Pearson’s Correlation Coefficient (R) Values For Vertex And Temporal Recording Of
40 Hz ASSR. Vertex data showed moderate correlation between session 1 and other sessions
(r>0.5), whereas temporal lead showed a poor and variable correlation. The data are from a
group of 12 rats.

Session 2

Session 3

Session 4

Time
Sessions
30 Minutes Session 1

Vertex
0.5314

Temporal
-0.1373

Vertex
0.6292

Temporal Vertex
-0.5094 0.5312

Temporal
0.1935

60 Minutes Session 1

0.6371

-0.169

0.6029

-0.1893

0.6707

0.1453

90 Minutes Session 1

0.7012

-0.03128

0.8724

-0.005014

0.5823

0.2794

120 Minutes Session 1

0.5818

-0.009851

0.6371

0.5857

0.5184

-0.05542

Then, we calculated CV, as a measure of individual animal’s response precision for 16
recordings (i.e., 4-time points x 4 sessions). Vertex 40 Hz ASSR showed a markedly lower mean
CV at 29.3 %. Whereas temporal 40 Hz ASSR showed a significantly higher mean CV at 71.2%.
Fig. 3.3 highlights the differences between these two measures as a violin plot (p=0.0001; paired
t-test).
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Figure 3.3. Summary of % CV of vertex and temporal 40 Hz ASSR evoked power from a group
of 12 rats. Dots and squares represent individual animals within the violin plots. Asterisks
indicate significant difference between the two groups (p <0.0001; paired t-test).
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Vertex-Recorded 40 Hz ASSR Showed A Dose-Dependent Reduction By MK-801
Next, we compared the sensitivity of vertex and temporal 40 Hz ASSR to open channel
NMDA blocker MK-801. We selected three doses of 0.025, 0.05 and 0.1 mg/kg MK-801 to
represent a range of NMDA channel blockade (Fernandes et al., 2015). Rats showed a
stereotyped behavior with head weaving and circumambulation after 0.1 mg/kg MK-801 that
lasted for up to 3 hours, whereas 0.025 or 0.05 mg/kg MK—801 did not induce any discernible
behavioral changes.
Vertex 40 Hz ASSR showed a highly dose-dependent reduction in ITC and evoked power
by MK-801. Mixed-effects ANOVA for ITC showed a robust treatment effect (p<0.0001; F
(2.214, 19.92) = 48.62; epsilon = 0.7379) but no time effect (p=0.3345; F (1.881, 16.93) = 1.159;
epsilon = 0.6271). However, there was a significant time × treatment interaction (p<0.05; F
(3.556, 30.02) = 3.648; epsilon = 0.3951). Post hoc comparisons using Dunnett’s test showed
that 0.05 and 0.1 mg/kg doses of MK801 significantly (p<0.01) attenuated vertex 40 Hz ASSR
ITC at multiple time-points, as compared to vehicle treatment (fig. 3.4-B).
Evoked power also showed a highly significant treatment effect (p<0.0001; F
(2.004, 18.04) = 38.66; epsilon = 0.6680) but no time effect (p= 0.3191; F (2.085, 18.77) =
1.220; epsilon = 0.6951) or time × treatment interaction (p=0.1120; F (2.245, 20.21) = 1.728;
epsilon = 0.4858). Post hoc analysis showed significant reduction (p<0.01) by only 0.05 and 0.1
mg/kg doses of MK801 at multiple time-points, as compared to vehicle treatment (fig. 3.4-C).
Fig. 3.4-A shows the group summary of ITC, and evoked power, at the 60 minutes-post vehicle
or MK-801 injection, represented as heat maps.
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(A)

(B)

(C)

Figure 3.4. Effect of MK-801 on vertex 40 Hz ASSR. Heat-map summaries of ITC and evoked
power (A) at 60 minutes after vehicle or 0.1 mg/kg MK-801 (sc) treatment. Group summaries of
ITC (B) and evoked power (C) data at 30, 60, 90 and 120 minutes after vehicle or MK-801
(0.025, 0.05, or 0.1 mg/kg, sc) treatment. Data are from a group of 10 rats. (**p<0.01,
***p<0.001, ****p<0.0001; Dunnett’s post hoc).

MK-801 Did Not Cause A Significant Attenuation In Temporal 40 Hz ASSR
In contrast to vertex, MK-801 did not show any significant effect on temporal 40 Hz
ASSR ITC and evoked power. Mixed-effects ANOVA for ITC showed no treatment effect
(p=0.1189; F (2.181, 19.63) = 2.342; epsilon = 0.7269). However, there was a significant time
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effect (p<0.0001; F (2.283, 20.54) = 2.342; epsilon = 0.7609), and a significant time × treatment
interaction (p<0.01; F (4.056, 36.05) = 5.353; epsilon = 0.4507). Post hoc comparisons using
Dunnett’s test showed that only 0.025 mg/kg MK801 significantly (p<0.05) increased temporal
40 Hz ASSR ITC only at 90 minutes time point, relative to vehicle treatment (fig. 3.5-B).

(A)

(B)

(C)

Figure 3.5. Effect of MK-801 on temporal 40 Hz ASSR. Heat-map summaries of ITC and
evoked power (A) at 60 minutes after vehicle or 0.1 mg/kg MK-801 (sc) treatment. Group
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summaries of ITC (B) and evoked power (C) data at 30, 60, 90 and 120 minutes after vehicle or
MK-801 (0.025, 0.05, or 0.1 mg/kg, sc) treatment. Data are from a group of 10 rats. (*p<0.05;
Dunnett’s post hoc).

Temporal 40 Hz ASSR evoked power also showed no treatment effect (p=0.0859; F
(1.915, 17.24) = 2.867; epsilon = 0.6385) with repeated measures ANOVA. Again, there was a
significant time effect (p<0.05; F (1.962, 17.66) = 4.585; epsilon = 0.6539), and a significant
time × treatment interaction (p<0.01; F (3.567, 32.91) = 5.339; epsilon = 0.4069). Post hoc
comparisons using Dunnett’s test showed that only 0.025 mg/kg MK801 significantly (p<0.05)
increased temporal 40 Hz ASSR evoked power at 90-, and 120-minutes time points, relative to
vehicle treatment (fig. 3.5-C). Fig. 3.5-A shows the group summary of ITC and evoked power at
the 60 minutes-post vehicle or MK-801 injection, represented as heat maps.

0.3 mg/kg Dose Of MK-801 Significantly Reduced 40 Hz ASSR From Both Vertex And Temporal
Recordings
In a follow up study, we administered a higher dose of MK-801 (0.3 mg/kg), which
caused significant reduction in both vertex and temporal recordings of 40 Hz ASSR. Fig. 3.6-A
shows the group summaries of ITC for vertex and temporal 40 Hz ASSR as heat maps for 60
minutes time point. Vertex recordings of 40 Hz ASSR showed no significant time effect
(p=0.4143; F (2.604, 26.04) = 0.9644; epsilon = 0.8679). In contrast, there was a highly
significant treatment effect (p<0.001; F (1.000, 10.00) = 32.65; epsilon = 1.000), and a
significant time × treatment interaction (p<0.01; F (2.360, 23.60) = 3.882; epsilon = 0.7868).
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Bonferroni post hoc comparisons showed a significant reduction in ITC by 0.3 mg/kg MK-801 at
all the timepoints (p<0.01-p<0.001), as compared to vehicle (fig. 3.6-B).

(A)

(B)

(C)

Figure 3.6. Effect of 0.3 mg/kg MK-801 on ITC of vertex and temporal 40 Hz ASSR. Heat map
summaries of ITC at 60 minutes (A). Group summaries of the ITC at 30, 60, 90 and 120 minutes
after vehicle or 0.3 mg/kg MK-801 treatment for vertex (B), and temporal (C) recordings of 40
Hz ASSR. Data are from a group of 11 rats. (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001);
Bonferroni post hoc).

For 40 Hz ASSR temporal recording, repeated measures ANOVA for ITC showed a
highly significant treatment effect (p<0.0001; F (1.000, 10.00) = 54.04; epsilon = 1.000), and a
significant time × treatment interaction (p<0.001; F (2.208, 22.08) = 12.31; epsilon = 0.7361).
However, there was no time effect (p=0.0899; F (2.199, 21.99) = 2.635; epsilon = 0.7330). Post
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hoc comparisons showed a significant reduction by 0.3 mg/kg MK-801 at 30, 60, and 90 minutes
timepoints (p<0.05-p<0.0001), as compared to vehicle (fig. 3.6-C).
Evoked power was also significantly affected by 0.3 mg/kg in both vertex and temporal
recordings of 40 Hz ASSR (fig. 3.7-A). Vertex 40 Hz ASSR showed a significant treatment
effect (p<0.0001; F (1.000, 10.00) = 44.83; epsilon = 1.000), and time × treatment interaction
(p<0.01; F (2.685, 26.85) = 5.300; epsilon = 0.8951) with repeated measures ANOVA. However,
there was no significant time effect (p=0.6747; F (2.210, 22.10) = 0.4310; epsilon = 0.7367).
Post hoc comparisons showed a significant reduction in vertex evoked power at all the time
points (p<0.05-p<0.001) by 0.3 mg/kg MK-801, relative to vehicle treatment (fig. 3.7-B).
Similarly, temporal recordings of 40 Hz ASSR showed a significant treatment effect
(p<0.05; F (1.000, 10.00) = 9.226; epsilon = 1.000), and a significant time × treatment
interaction (p<0.01; F (2.414, 24.14) = 5.936; epsilon = 0.8048). However, there was no
significant time effect (p=0.4583; F (1.769, 17.69) = 0.7815; epsilon = 0.5896). Post hoc
comparisons showed that 0.3 mg/kg MK801 significantly reduced 40 Hz ASSR only at 30
minutes timepoint (p<0.05-p<0.001), relative to vehicle treatment (fig. 3.7-C).
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(A)

(B)

(C)

Figure 3.7. Effect of 0.3 mg/kg MK-801 on evoked power of vertex and temporal 40 Hz ASSR.
Heat map summaries at 60 minutes time point (A). Group summaries of the evoked power at 30,
60, 90 and 120 minutes after vehicle or 0.3 mg/kg MK-801 treatment for vertex (B), and
temporal (C) recordings of 40 Hz ASSR. Data are from a group of 11 rats. (*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001); Bonferroni post hoc).
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Discussion
The 40 Hz ASSR is a promising tool to probe the neural synchrony of cortical
populations, evoked to oscillate at the gamma frequency (Uhlhaas and Singer, 2010). Gamma
oscillations play an essential role in sensory processing and integrating neural activity across
brain areas (Tallon-Baudry and Bertrand, 1999; Cardin, 2016). The utility of 40 Hz ASSR as a
translational biomarker for gamma oscillations depends on its thorough characterization
including the best coordinates for a robust and reliable signal. With this in mind, the first part of
this study tried to ascertain how recording sites may affect the 40 Hz ASSR.
Different techniques like low-resolution electroencephalographic tomography
(LORETA), minimum norm (MinNorm), and independent component analysis to map the source
of ASSR through current density reconstruction have revealed several cortical and subcortical
areas as generators of ASSR (Reyes et al., 2005; Farahani et al., 2017). These areas may process
auditory signals in a hierarchical or parallel fashion (Reyes et al., 2005).
There have been contrasting results regarding the source of 40 Hz ASSR. Some studies
have reported primary auditory cortex as a core structure for auditory processing with the highest
40 Hz ASSR sensitivity and amplitude (Herdman et al., 2003; Draganova et al., 2008; Wilson et
al., 2008; Brugge et al., 2009; Wang et al., 2018). In contrast, other studies have reported widely
distributed neural circuits in the parietal, frontal and temporal cortices as putative sources of the
40 Hz ASSR (Tada et al., 2019; Krom et al., 2020). Medial geniculate body (MGB) in the
auditory thalamus is traditionally considered as the primary relay center for auditory stimuli that
get routed through the so-called lemniscal pathway, which feeds forward the information to
higher cortical areas, especially the primary auditory cortex (Bartlett, 2013). However, studies
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have shown that there are other non-canonical thalamic nuclei involved in non-lemniscal
auditory processing that innervate a wide range of brain areas through feedforward and feedback
connections (Lee, 2015).
Notwithstanding the multiple pathways for auditory processing referred above, because
electrical activity responsible for ASSR may travel through volume conduction, it is conceivable
that the same ASSR signal is recorded at different intensities from different sites through
EEG/MEG. This is a fundamental question that needs an answer. In the current study, we
recorded ASSR from two distinct areas (Vertex and temporal), simultaneously. As the principle
of volume conduction suggests, a traveling wave in the form of neural oscillation will lose its
intensity (amplitude) as it travels farther from the source. Moreover, it will show higher latencies
at farther distances from the primary source. We wanted to test whether recordings from vertex
and temporal areas indicate a common source or two different sources for 40 Hz ASSR. Our
results showed a several folds higher temporal 40 Hz ASSR (evoked power and ITC) as
compared to vertex, which can be explained through volume conduction if temporal cortex is
considered as the primary source for 40 Hz ASSR. Under such conditions, vertex recordings of
the 40 Hz ASSR, which are being relayed from the temporal cortex, will show a weaker 40 Hz
ASSR, as seen in the current study. However, we did not see any difference in latencies, as
suggested by the volume conduction principle (fig. 2 supp). Previously, other studies have also
reported stronger ITC and evoked power of 40 Hz ASSR from the temporal region as compared
to vertex (Kozono et al., 2019). This observation is confirmed in our study. These findings can
alternatively be explained simply as vertex and temporal regions as two separate sources,
generating 40 Hz ASSR with different intensities. Our follow up pharmacological study (see
below) substantiates this position. Moreover, as discussed previously, there was a significant
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difference in the variance of the signal between vertex and the auditory cortex. We also
performed correlation analysis for the evoked power across sessions from vertex and temporal
recordings of 40 Hz ASSR. There was a moderate correlation between sessions for vertex
recorded ASSR; , temporal recordings showed a poor correlation between session 1 and the rest
of the sessions (table 3.2). This further suggests that 40 Hz recordings from these two areas
represent two distinct sources of 40 Hz ASSR. Of course, It is possible that they are not
completely independent and may interact with each other in some way that is not obvious at this
time.
As far as we know, there are no previous reports of studies comparing two recording sites
in terms of their reliability over an extended period of time. Thus, we measured the test-retest
reliability of 40 HZ ASSR recordings from vertex and temporal areas obtained over a period of
two weeks by calculating their ICC. Vertex 40 Hz ASSR showed a good test-retest reliability,
while temporal 40 Hz ASSR had poor test-retest reliability. Analysis of % coefficient of
variation further revealed a higher data dispersion for temporal 40 Hz ASSR, as compared to
vertex. To our knowledge, this is the first study to compare the test-retest reliability of 40 Hz
ASSR simultaneously recorded from two different areas in rodents. The reliability of 40 Hz
ASSR as a biomarker is important for translational application in psychiatric research. Previous
studies have reported 40 Hz ASSR from vertex region (i.e., Cz electrode) to show good testretest reliability in humans (McFadden et al., 2014; Hirano et al., 2020) and rodents (Raza and
Sivarao, 2021). Consistent results from human and animal studies provide compelling evidence
for the potential of 40 Hz ASSR as a reliable biomarker, recorded specifically from the vertex
region.
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In the next part of this study, we tested the responsivity of 40 Hz ASSR from vertex and
temporal regions. MK801 doses (0.025, 0.05, and 0.1 mg/kg) were selected to span a range of
occupancies (20-60%; Fernandes et al., 2015). At these doses, vertex 40 Hz ASSR showed
reduction by MK-801 in a dose-dependent manner, while temporal 40 Hz ASSR was largely
unaffected, although 0.025 mg/kg dose only caused a significant increase in evoked power and
ITC at certain time points. However, there is a precedent from studies showing augmented 40 Hz
ASSR by NMDA antagonists with low to moderate affinity and rapid kinetics like ketamine
(Plourde et al., 1997) and memantine (Light et al, 2017; Raza and Sivarao, unpublished data).
This may suggest that low-dose NMDA antagonists may be useful to improve 40 Hz circuit
function. However, a feature that would most certainly limit the utility of low-dose NMDA
antagonists like ketamine to improve ASSR response would be the concomitant increase in the
background or non-stimulus-related gamma power, regarded as a neurophysiological signature
for noise (Pinault, 2008, 2014). The qualitatively different responses noted for vertex ASSR vs.
temporal ASSR suggests that these sources may be substantially different from each other. In a
follow-up study, we tested a higher MK-801 dose (0.3 mg /kg) that shows an NMDAR
occupancy close to saturation (Fernandes et al. 2015). At this high dose of MK-801, both vertex
and temporal 40 Hz ASSR were significantly attenuated (fig. 3.6).
Previously, there have been contradictory results regarding the effect of NMDAR
inhibition through pharmacological or genetic manipulations on 40 Hz ASSR. Studies have
reported, no change (Sullivan et al., 2015), a decrease followed by an increase (Plourde et al.,
1997); Vohs et al., 2012; O’Donnell et al., 2013; Leishman et al., 2015; Sullivan et al., 2015) or
decrease (Sivarao et al., 2013; Raza and Sivarao, 2021; Schuelert et al. 2018) in 40 Hz ASSR in
response to disruption of NMDAR transmission in rodents and humans. Based on these findings,
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it appears that the choice of the NMDA antagonist may have a bearing on the kind of response
one sees. For example, ketamine is a low affinity (Ki ~ 330 nM) antagonist that shows rapid onoff kinetics at the NMDA receptor (Wallach et al., 2016). Thus, sustained and substantive
blockade at the receptor site is hard to achieve. On the other hand, MK801 (Ki, 2.5 nM) can
result in a relatively irreversible and long-lasting blockade of the NMDA channel (Hakami et al.,
2009; Davies et al., 1988). Indeed, genetic ablation of NMDAR, specifically on PV+ neurons,
consistently results in reduction of 40 Hz ASSR in rodents (Carlén et al., 2012; Nakao and
Nakazawa, 2014).
In summary, 40 Hz ASSR recorded from vertex consistently showed high test-retest
reliability and was highly sensitive to NMDAR inhibition, as reported previously (Raza and
Sivarao, 2021). Whereas temporal 40 Hz ASSR showed poor test-retest reliability and lower
sensitivity to MK-801 treatment. Previous studies have consistently reported 40 Hz ASSR
deficits in schizophrenia patients (Kwon et al., 1999; Brenner et al., 2003; Light et al., 2006;
Krishnan et al., 2009; Spencer et al., 2009). Thus, results from the current study further support
that vertex area represents an attractive region for recording 40 Hz ASSR in rodent models,
given its test-retest reliability and high sensitivity to NMDA antagonism. Furthermore, 40 Hz
ASSR recorded from vertex and temporal sites seems to originate from two distinct circuits, with
different degrees of reliability and sensitivity toward NMDA antagonists. Our study fills an
important gap in the context of optimizing 40 Hz ASSR recording paradigms in rodent models.
Standardization of 40 Hz ASSR recording procedures will enable a way to compare data across
laboratories and studies.
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CHAPTER 4. A UNIQUE PROFILE OF CLOZAPINE IN IMPROVING 40 HZ ASSR AND
ITS PROTECTION AGAINST MK-801-INDUCED DISRUPTION
Abstract
Rationale. Previously, we have shown that MK-801 treatment causes a dose-dependent reduction
in 40 Hz ASSR from vertex recordings. For 40 Hz ASSR to be useful pharmacodynamic
biomarker, it needs to be bidirectionally modulated by drug treatment. Therefore, in the current
study, we tested the hypothesis if 40 Hz ASSR can be augmented by D-serine (an NMDAR coagonist), or with antipsychotic treatment.
Objective. We investigated whether treatment with D-serine, or an antipsychotic can enhance 40
Hz ASSR. Furthermore, we investigated the protective effect of these drugs on MK-801-induced
disruption in 40 Hz ASSR
Methods. We carried out six separate studies testing the effect of D-serine, haloperidol (a typical
antipsychotic), or clozapine (an atypical antipsychotic) treatment only or before MK-801
treatment, in a crossover study design. D-serine doses selected for this study (30-500 mg/kg, SC)
have shown to cause a robust increase in extracellular D-serine levels in the brain. Moreover,
doses for clozapine and haloperidol were chosen to reflect clinically relevant D2 occupancy.
Auditory stimuli were presented (1KHz tone, 50 msec duration, and 40 clicks for 1 second (40
Hz), 65 dB, 3-sec ITI, 5- sec sweeps, 75 trials) at 30, 60, 90- and 120-minutes post-treatment.
Recordings were made from the vertex electrode using a cerebellar reference. In the D-serine, or
antipsychotics pre-treatment studies, drugs were administered 20 minutes before MK-801 (0.1
mg/kg, SC) administration. ASSR was recorded at 30, 60, 90- and 120-minutes post-MK-801
injection.
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Results. Treatment with D-serine (30, 60, or 120 mg/kg, SC) did not have any effect on 40 Hz
ASSR. Similarly, pretreatment of D-serine with relatively higher doses (250, or 500 mg/kg, SC)
did not provide any protection against MK-801 induced disruption in 40 Hz ASSR. As compared
to haloperidol (0.02, 0.04, or 0.08 mg/kg, SC), which showed no improvement in 40 Hz ASSR,
treatment with clozapine (2.5, 5, and 10 mg/kg, SC) caused a significant improvement in the 40
Hz ASSR (evoked power, and ITC) in a dose and time-dependent manner. Furthermore, only
clozapine (10 mg/kg, SC) showed a partial protection against MK-801-induced 40 Hz ASSR
deficits (ITC, and evoked power), whereas haloperidol (0.04, or 0.08 mg/kg, SC) had no
ameliorative effect against MK-801. Moreover, as shown previously (Raza and Sivarao, 2021),
MK801 produced robust deficits in 40 Hz ASSR in all MK-801 related studies.
Conclusion. These studies highlight the following: 1. Only clozapine improves sensory
transmission by itself; 2. Pretreatment with only clozapine is partially protective against NMDA
disruption; 3. Our work illustrates the utility of the 40 Hz ASSR as a circuit-based
pharmacodynamic biomarker, which can be bidirectionally modulated by pharmacological
treatment.
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Introduction
Schizophrenia is a serious mental disorder exhibiting psychotic, emotional, and cognitive
symptoms. Currently available antipsychotics target dopamine D2 receptors and are effective in
managing psychosis but remain ineffective against negative and cognitive symptoms (Leucht et
al., 2009). Unlike psychotic symptoms, which often wax and wane, negative and cognitive
symptoms are persistent throughout the duration of the disease. Considerable evidence now
supports negative and cognitive symptoms as the core feature of schizophrenia, impacting patient
outcomes over the long-term (Gold, 2004; Hyman and Fenton, 2003; Üçok et al., 2013).
Cognitive and negative symptoms also precede psychosis onset and may determine real world
functioning ability of the affected patients (Green and Nuechterlein, 1999; Green, 2006).
Over the years, the N-methyl D-aspartic acid receptor (NMDAR) hypofunction
hypothesis has gained traction as a way to explain the symptomatology of schizophrenia. It
started from the observation that non-competitive NMDAR antagonists like phencyclidine (PCP)
and ketamine induce schizophrenia-like symptoms, including behavioral and cognitive
symptoms, in healthy humans (Allen and Young, 1978; Luby et al., 1962). Furthermore,
NMDAR antagonists were shown to exacerbate schizophrenia symptoms in recovering patients
(Javitt and Zukin, 1991). Interestingly, dosing preclinical species with NMDA antagonists has
resulted in cognitive (e.g., attention, working memory) (Egerton et al., 2005), behavioral (e.g.,
social interaction, stereotyped behavior) (Murray and Horita, 1979; Sams-Dodd, 1995), and
sensory motor deficits (e.g., MMN, sensory gating, PPI) (Mansbach and Geyer, 1989; Bristow et
al., 2016) mimicking schizophrenia like symptoms. This has led to the evaluation of NMDAR
targeted therapies, which have shown modest effects in small clinical trials (for a review, see
Singh and Singh, 2011), mainly based on symptom improvement (Ermilov et al., 2013). It is to
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be noted that these trials did not use any objective biomarkers for demonstrating D-serine
induced changes, short of the symptomatic improvement. In the absence of objective
biomarkers, despite encouraging symptomatic data, there is a reluctance in the pharmaceutical
industry to invest in large scale clinical trials to evaluate new and emerging targets
(Venkatasubramanian & Keshavan, 2016).
In previous chapters, I have discussed how vertex-recorded 40 Hz ASSR is exquisitely
sensitive to NMDA mechanism. This is also a response that we have replicated multiple times in
our experiments, which indicates a high degree of reliability. For an index like 40 Hz ASSR to
be useful as a pharmacodynamic biomarker, it needs to be bidirectionally modulated by drug
treatment. Since acute treatment with NMDA channel blocker attenuated the 40 Hz ASSR
response, we hypothesized that any pharmacological intervention designed to increase NMDAR
activation may do the opposite. We evaluated this in several stages. One, we tested the effect of
a wide range of doses of D-serine, a co-agonist at the glycine-modulatory site on the NMDA
receptor (Balu and Coyle, 2015). In a follow up study, we gave MK801 minutes following Dserine administration to see if D-serine would blunt the effect of MK801 on the 40 Hz ASSR
measure. We saw no evidence for D-serine augmenting the 40 Hz ASSR by itself or blunting the
effect of MK801 on the 40 Hz ASSR.
In the next part of the study, we evaluated the effect of an atypical antipsychotic
clozapine at doses that mimic clinically relevant D2 receptor occupancy, on the 40 Hz ASSR.
Clozapine robustly and dose-dependently improved 40 Hz ASSR. However, haloperidol, a
typical antipsychotic, at doses shown to yield comparable D2 occupancy, showed no effect on
the 40 Hz ASSR. Lastly, pretreatment with clozapine but not haloperidol blunted the effect of a
subsequent dose of MK801-mediated disruption of the 40 Hz ASSR.
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Methods

General
6–8-week-old female Sprague Dawley rats (150–200 g) were purchased from Envigo
(Indianapolis, IN) and were placed in group housed environment with free access to food and
water. After surgery animal were housed individually to prevent damage to the head-mounted
EEG hardware. All the experimental procedures on animals were approved by the Institutional
Animal Care and Use Committee of the East Tennessee State University (#180901).

Surgery
All surgeries were performed as described previously (Raza and Sivarao, 2021). In Brief,
animals were anaesthetized with 5% isoflurane (induction 5%; maintenance, 1-2% with 1 L/min
oxygen. The head area was shaved and then was secured in a stereotaxic frame. Alcohol and
povidone-iodine swabs were used to clean the surgery area. Bupivacaine (0.25 %, 8mg/kg, sc)
was infiltrated through the subcutaneous field as a local anesthesia and ketoprofen (5 mg/kg, sc)
was used for perioperative analgesia. A midline incision was made, and membranes were
scraped through blunt dissection to expose the skull. A solution of 3% hydrogen peroxide was
introduced drop by drop to disinfect the area and was mopped up and dried. Four burr holes were
made into the skull using an aseptic drill bit at the following coordinates: 1mm anterior and 1mm
lateral (right) to bregma (targeting the prefrontal cortex), 4.5 mm posterior and 1mm lateral (left)
to bregma (targeting the vertex region), 2 mm posterior and 2mm lateral (left) to lambda
(reference), and 2 mm posterior and 2 mm lateral (right) to lambda (ground). Electrodes with
attached wires were gently screwed into the burr holes while keeping the underlying dura intact.
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Electrodes were completely covered with dental cement. A recording head mount (Pinnacle
Technology, Lawrence, KS) was placed on the dental cement after it had cured, and electrode
wires were attached to the head mount wires with a solder. All the exposed wires were covered
with a second layer of dental cement. The surgery area was closed with sutures and rats were
given at least 10 days to recover. After recovery, rats were handled and acclimated to the
recording set up several times on separate days before any experiments were started.

EEG Recording Protocol
Rats were placed in the recording chamber for at least 10 minutes before starting each
experiment. EEG recordings were carried out as described previously (Raza and Sivarao, 2021).
Rats were connected to the recording setup through a shielded cable fitted with a head stage
preamplifier (10X) (Pinnacle Technology, Lawrence, KS). The EEG signals were routed through
an analog adapter, to a differential amplifier (100X; DP-304A, Warner Instruments Inc). Thus,
the EEG signal was amplified a thousand-fold. The amplified signal was acquired by an analog
to digital conversion board (CED Micro 1401-3). The auditory stimuli were presented through 3”
4-Ohm house speakers (DROK, B00LSEVA8I), fixed at the center of the ceiling of each
recording chamber. Auditory stimuli including a tone and a 40 Hz click train were produced in
Signal v7.01 software and delivered through the acquisition system (CED Micro 1401-3;
Cambridge Electronics Design (CED), Cambridge, UK), which also concurrently recorded the
EEG as consecutive sweeps. A 1 KHz tone as a sinusoidal wave with 50 msec duration and 65
dB intensity was presented a second after a 5 s sweep stimulus was initiated. The tone stimulus
was followed by a train of 40 clicks for a duration of 1 sec (40 Hz), 3 seconds after the sweep
initiation. In the D-serine study only, the duration of click-trains lasted for 2 sec, delivering a
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total of 80 clicks. In all experiments, the 40 Hz click train had an intensity of 65 dB, as measured
by a sound pressure meter and each click resulted from a 1 ms 3 or 5 V square wave that was fed
to the house amplifier. Inter-stimulus interval (ISI) between tone stimulus and 40 Hz click train
was 2 sec in each trial, while the inter-trial interval (ITI) between the end of 40 Hz click train and
the next tone stimulus was 3 sec. The auditory stimuli were repeatedly presented in 75 trials. In
this study, we report the EEG data recorded only from vertex electrode. EEG data was recorded
at 30, 60, 90 and 120 minutes in four sessions, as typically there were four total treatments in this
cross-over design. A washout period of at least 3 days was allowed between recording sessions.

EEG Data Analysis
The use of head stage amplification (10X; Pinnacle Technologies) greatly reduced
movement artifacts, however chewing-associated artifacts were present intermittently. The trial
exclusion criteria followed the removal of a trial if an artifact coincided with the auditory
stimulus duration, thus typically <5% the 75 trials were excluded. The preliminary data analysis
was performed using the Signal v7.01 software. Artifact free trials were averaged for each rat.
Averaged trials clearly showed tone-evoked event related potential (ERP) and 40 Hz click trainevoked ASSR (fig. 3 supp). Although, both tone and 40 Hz click-train stimuli were presented,
we focused only on analyzing 40 Hz ASSR. Evoked response for the tone stimulus was used
only as a reference. Averaged trials were then digitally band-pass filtered to 35-45 Hz through
2nd order Butterworth, zero-phase shift, infinite impulse response (IIR) filter. The group
averages were obtained from the averaged trials to represent summary results.
Time-frequency analysis (TFA) was performed in the EMSE data editor software v5.6.1
(Cortech solutions, Wilmington, NC). Raw data files from signal software v7.1 were first
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exported as text files and imported into EMSE v5.X software (Cortech Solutions Inc.,
Wilmington, NC). TFA was performed through Morlet transformation to measure evoked power
and inter-trial phase coherence (ITC). ITC (also known as phase synchrony or phase locking
factor (PLF) is a measure of trial-to-trial phase consistency in the 40 Hz ASSR, while evoked
power is the measure of averaged 40 Hz ASSR power. Both ITC and evoked power measure 40
Hz ASSR signal, which is time-locked to stimulus onset (Brian J. Roach and Mathalon, 2008).
Peak and area measurements of 40 Hz ASSR for ITC and evoked power were obtained to
perform statistical analysis. The initial 0.2 milliseconds of evoked response from the ASSR were
excluded for measurements (fig. 3 supp). The initial response (i.e., ~200 milliseconds) is
considered transient response, or transient gamma band response (tGBR), and is a broadband
frequency response (Pantev et al., 1993). Whereas the response period after ~ 200 milliseconds
represent cortical entrainment to the modulating frequency as ASSR (i.e., 40 Hz ASSR in the
current study) (Hari et al., 1989). TFA was also performed on the concatenated data from each
group to obtain summary results for representation.

Pharmacology
D-serine study. D-serine (Sigma-Aldrich) was dissolved in 0.9% sterile saline to make
1g/ml stock solution, which was kept in aliquots at -20 oC. Fresh dilutions were made from the
stock solution before the start of each experiment. In the D-serine only study, rats were injected
with either vehicle or D-serine (30, 60, and 120 mg/kg, SC). Whereas in the D-serine pretreatment study, rats were first injected with either vehicle or D-serine (250, and 500 mg/kg, SC).
Then after at least 20 minutes rats were injected again either with vehicle or 0.1 mg/kg MK-801.
MK-801 maleate (Sigma-Aldrich) was dissolved in 0.9% sterile saline to obtain 0.1 mg/ml MK-
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801 free base solution and was stored at 4oC in aliquots. ASSR recording were made at 30-, 60-,
90- and 120-minutes time points. Animals were given at least 3 days for the washout period and
the same procedure was repeated. A cross-over design was followed which spanned across 4
session for 2 weeks.
Clozapine study. Clozapine (Sigma-Aldrich) was dissolved in glacial acetic acid (50 ml).
Then 0.9% sterile saline was added to make stock solution of 10mg/ml with the final acetic acid
concentration of 10%. The final pH was adjusted to 6.0 by adding sodium bicarbonate. Dilutions
at 2.5 and 5 mg/ml clozapine were made from the 10 mg/ml stock solution. Fresh clozapine
solutions were prepared before each recording session. The vehicle solution (i.e., 0.9 % saline)
also had pH of 6.0. In the clozapine only study, rats were injected with either vehicle or
clozapine (2.5, 5, and 10 mg/kg, SC) While in clozapine pretreatment study, rats were pre-treated
with either vehicle or clozapine (5, and 10 mg/kg, SC). Then after at least 20 minutes, rats were
injected again either with vehicle or 0.1 mg/kg MK-801. ASSR recordings were carried out as
described above.
Haloperidol study. Haloperidol (Sigma-Aldrich) stock solution at 0.8 mg/ml was made
following the same protocol as for clozapine solution. Dilutions were made at 0.02 and 0.04
mg/ml from the stock solution. The final pH of vehicle for haloperidol study was also adjusted to
6.0. In the haloperidol only study, rats were injected with either vehicle or haloperidol (0.02,
0.04, and 0.08 mg/kg, SC). In the haloperidol pre-treatment study, rats were first injected with
either vehicle or haloperidol (0.04, and 0.08 mg/kg, SC). Then after at least 20 minutes rats were
injected again either with vehicle or 0.1 mg/kg MK-801. ASSR recording were made at 4 time
points across 4 sessions, as described in the D-serine section above.
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In the literature, wide range of D-serine doses have been used from as low as 30 mg/kg to
as high as 2g/kg. We followed previous studies (Fone et al., 2020; Hasegawa et al., 2019) to
choose D-serine dose ranges (30-500 mg/kg). These doses show a significant increase in brain
D-serine levels as compared to baseline without significantly increasing creatine levels. Doses
selected for clozapine (2.5-10 mg/kg) and haloperidol (0.02-0.08 mg/kg) have been reported to
yield clinically relevant D2 receptor occupancy, after acute dosing (Kapur et al., 2003; Seeman
and Kapur, 2000). A schematic of the study designs is shown in fig. 4.1 (A and B).

Statistical Analysis
The first key objective of the study was to measure the improvement in 40 Hz ASSR
caused by D-serine or antipsychotics by themselves. While the second objective was to measure
the protective effect of D-serine or antipsychotics pretreatment on MK-801-induced disruption.
A two-way analysis of variance (ANOVA) repeated measures design (mixed-effect model;
GraphPad Prism, v9.1) was implemented to determine treatment effect. Time of recording and
treatment groups were selected as row and column factors, respectively. Quantile-quantile (q-q)
plot was used to ensure data normality. In case the data are non-linear, which happened
infrequently, we log transformed the data first to confirm linearity and then, parametric statistics
were applied. Greenhouse-Geisser correction was implemented without assuming sphericity.
Dunnett’s post hoc analyses were used to measure treatment significance and vehicle group or
vehicle + MK-801 group were selected as comparators.
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10
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Repeated after > 3 days

Figure 4.1. Schematic representations of the study design. Vehicle, antipsychotics, or D-serine
only (A), and vehicle, antipsychotics, or D-serine pretreatment before MK-801 pharmacology
study (b). (sc) subcutaneous.
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Results

D-Serine Showed No Effect On 40 Hz ASSR And Did Not Prevent MK-801-Induced Deficits
In the first study, we treated rats with vehicle or D-serine (30-120 mg/kg) alone. There
was no effect of D-serine on 40 Hz ASSR. Mixed-effects ANOVA showed no significant
treatment effect of D-serine on ITC (p=0.15; F (2.2, 19.4) = 2.03; epsilon = 0.72). There was no
significant time effect (p=0.34; F (2.418, 21.76) = 1.132; epsilon = 0.80), or time x treatment
interaction (p=0.34; F (4.202, 37.81) = 0.6522; epsilon = 0.47). Similarly, evoked power also
showed no significant treatment effect (p=0.15; F (2.291, 20.62) = 1.993; epsilon = 0.76), time
effect, (p=0.29; F (2.109, 18.98) = 1.311; epsilon = 0.70), or time x treatment interaction
(p=0.63; F (3.618, 32.56) = 0.6199; epsilon = 0.40). Fig. 4.2 shows the group summaries of ITC
(A) and evoked power (B) at 30, 60, 90 and 120 minutes after vehicle or 30-120 mg/kg D-serine
treatment.

(A)

(B)
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Figure 4.2. Effect of D-serine on 40 Hz ASSR. Group summaries of ITC (A) and evoked power
(B) of 40 Hz ASSR at 30, 60, 90 and 120 minutes after vehicle or D-serine treatment. Data are
from a group of 10 rats. (Dunnett’s post hoc, vehicle comparator). (ITC) inter-trial coherence.

Next, we tested the protective effect of relatively higher doses of D-serine (250-500
mg/kg) pretreatment on MK-801-induced disruption in 40 Hz ASSR (fig. 4.3-A).
Mixed-effects ANOVA showed a significant treatment effect (p<0.001; F (1.436, 14.36)
= 14.83; epsilon = 0.48), while no significant time effect (P=0.70; F (2.154, 21.54) = 0.3808;
epsilon = 0.72) or time x treatment interaction (P=0.09; F (4.097, 40.97) = 2.15; epsilon = 0.72).
Dunnett’s post hoc analysis showed a significant reduction in evoked power by 0.1 mg/kg MK801 at all-time points (p<0.05-p<0.01), as compared to vehicle groups. However, pretreatment
with D-serine showed no significant protection against MK-801 induced disruption. Fig. 4.3-B
shows the group summaries of evoked power.
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(B)
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Figure 4.3. Effect of D-serine pretreatment on MK-801-induced deficits in 40 Hz ASSR. A
compilation of grand averages of 35-45 Hz filtered 40 Hz ASSR 60 minutes after MK-801
treatment (A). Group summaries of evoked power of 40 Hz ASSR at 30,60,90 and 120 minutes
after MK-801 treatment (B). Data are from a group of 10 rats. Asterisks indicate significant
differences between vehicle + vehicle and vehicle + MK-801 groups (*p<0.05, **p<0.01;
Dunnett’s post hoc, vehicle + MK-801 comparator). (ITC) inter-trial coherence.

Clozapine By Itself Improved 40 Hz ASSR In A Dose Related Manner
Our results showed a significant augmentation in 40 Hz ASSR after treatment with
clozapine in a dose related manner. Mixed-effect ANOVA showed a significant treatment effect
on ITC across all time points from 30-120 minutes post-vehicle or clozapine injection (p<0.0001;
F (2.6, 28.4) = 33.10; epsilon = 0.86). However, no significant time effect (P=0.38; F (2.4, 26.6)
= 1.04; epsilon = 0.80) or time x treatment interaction (P=0.57; F (5.9, 65.3) = 0.79; epsilon =
0.66) was seen. Evoked power also showed a significant treatment effect (p<0.001; F (2.433,
26.76) = 10.69; epsilon = 0.81), while no significant time effect (P=0.75; F (2.610, 28.71) =
0.36; epsilon = 0.87) or interaction of time x treatment (P=0.27; F (5.290, 58.19) = 1.289; epsilon
= 0.59) was observed. Fig. 4.4 shows the group summary of ITC (A) and evoked power (B) at
the 30 minutes-post vehicle or clozapine injection, represented as heat maps. Dunnett’s post hoc
analysis showed a significant increase in ITC by 5 (p<0.01-p<0.001) and 10 mg/kg (p<0.05p<0.0001) clozapine doses across all time points, as compared to vehicle. While increase in ITC
by 2.5 mg/kg clozapine was significant up to 90 minutes post-injection (p<0.05-p<0.001).
Moreover, 10 mg/kg clozapine significantly increased evoked power up to 90 minutes time point
(p<0.05-p<0.001), whereas 2.5 and 5 mg/kg clozapine showed significant improvement at only
30 minutes post-injection (p<0.05 and P<0.01, respectively). Fig. 4.4-C and D summarizes the
dose and time course effects of vehicle or clozapine (2.5, 5 or 10 mg/kg) on ITC and evoked
power
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Figure 4.4. Effect of clozapine on 40 Hz ASSR. Heat-map summaries of ITC (A) and evoked
power (B) of 40 Hz ASSR at 30 minutes after vehicle or clozapine (2.5, 5, or 10 mg/kg, sc)
treatment. Group summaries of ITC (C) and evoked power (D) data at 30,60,90 and 120 minutes
after vehicle or clozapine treatment. Data are from a group of 11 rats. (*p<0.05, **p<0.01,
***p<0.001, ****p<0.0001; Dunnett’s post hoc; vehicle comparator). (ITC) inter-trial
coherence.

Clozapine Pretreatment Partially Protected Against MK-801-Induced Deficits In 40 Hz ASSR
Next, we tested if clozapine could improve MK-801-induced deficits in 40 Hz ASSR
measures. Rats were given either vehicle only, vehicle before 0.1 mg/kg MK-801 treatment, or 5
or 10 mg/kg clozapine before MK-801 treatment. Mixed-effects ANOVA showed a highly
significant effect of treatment (P<0.0001; F (2.1, 19.0) = 19.37; epsilon = 0.70) and a significant
time x treatment interaction (P<0.05; F (4.9, 44.0) = 3.19; epsilon = 0.54) but no time effect
(P=0.69; F (2.7, 24.1) = 0.46; epsilon = 0.89) on ITC. Fig. 4.5 represents TFA heat maps of
concatenated group data for ITC (A) and evoked power (B) at 60 minutes. Dunnett’s post hoc
analysis showed a highly significant MK-801-induced reduction in ITC (fig. 4.5-C) at 60, 90 and
120 minutes as compared to vehicle + vehicle group (p<0.01-p<0.0001). Pretreatment with 10
mg/kg clozapine significantly protected against MK-801-induced reduction in ITC at only 60and 120-minutes time-points (P<0.05), while 5 mg/kg clozapine showed significant protection at
only 120 minutes (p<0.05, vehicle + MK-801 comparator).
Evoked power also showed a significant treatment effect (P<0.0001; F (2.222, 20.00) =
20.20; epsilon = 0.74) and a significant time x treatment interaction (P<0.05; F (4.938, 44.44) =
2.74; epsilon = 0.54) but no time effect (P=0.97; F (2.911, 26.20) = 0.075; epsilon = 0.97). In
post hoc analysis, 10 mg/kg clozapine group showed a highly significant protective effect on
evoked power at 60, 90 and 120 minutes (p<0.01), while 5 mg/kg group was only significantly
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protective at 60 minutes as compared to vehicle + MK-801 group. Moreover, the protective
effect of clozapine pretreatment on ITC and evoked power was partial against MK-801 induced
disruption. Group summary results are presented in fig. 4.5 (C and D).
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Figure 4.5. Effect of clozapine pretreatment on MK-801-induced disruption in 40 Hz ASSR.
Heat-map summaries of ITC (A) and evoked power (B) of 40 Hz ASSR at 30 minutes after
vehicle or MK-801 treatment. Group summaries of ITC (C) and evoked power (D) data at 30, 60,
90 and 120 minutes after vehicle or MK-801 treatment. Data are from a group of 10 rats.
Asterisks indicate significant differences between vehicle + vehicle and vehicle + MK-801
groups (**p<0.01, ***p<0.001, ****p<0.0001), while number sign represent significant
differences between vehicle + MK-801 and clozapine + MK-801 groups (#p<0.05, ##p<0.01;
Dunnett’s post hoc, vehicle + MK-801 comparator). (ITC) inter-trial coherence.

Treatment With Haloperidol Did Not Improve 40 Hz ASSR
There was no improvement observed in 40 Hz ASSR after haloperidol treatment. Mixedeffects ANOVA showed no significant effect of haloperidol treatment on ITC (p=0.86; F (1.8,
14.2) = 0.12; epsilon = 0.59), also there was no significant time effect (p=0.15; F (1.849, 14.79)
= 2.164; epsilon = 0.61), or time treatment interaction (p=0.31; F (3.422, 27.37) = 1.246; epsilon
= 0.38). Evoked power also did not show any significant treatment effect (p=0.45; F (1.869,
14.95) = 0.82; epsilon = 0.62), no significant time effect (p=0.09; F (2.294, 18.35) = 2.58;
epsilon = 0.76), or time x treatment interaction (p=0.12; F (4.001, 32.01) = 1.955; epsilon =
0.44). Fig. 4.6 shows heat maps of ITC (A) and evoked power (B) at 30 minutes after vehicle or
0.02-0.08 mg/kg haloperidol treatment. Results are presented as group summaries in fig. 4.6 (C
and D).
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Figure 4.6. Effect of haloperidol on 40 Hz ASSR. Heat-map summaries of ITC (A) and evoked
power (B) of 40 Hz ASSR at 30 minutes after vehicle or haloperidol (0.02, 0.04, or 0.08 mg/kg,
sc) treatment. Group summaries of ITC (A) and evoked power (D) data at 30, 60, 90 and 120
minutes after vehicle or haloperidol treatment. Data are from a group of 9 rats. (ITC) inter-trial
coherence. Dunnett’s post hoc, and vehicle comparator.

Haloperidol Pre-Treatment Had No Ameliorative Effect Against MK-801-Induced Disruption
Pretreatment with haloperidol also had no protective effect against MK-801-induced
disruption of 40 Hz ASSR. Mixed-effects ANOVA revealed a highly significant treatment effect
for ITC (p<0.0001; F (1.8, 12.6) = 24.51; epsilon = 0.6). There was also a significant time effect
(p<0.001; F (1.427, 9.989) = 22.56; epsilon = 0.47), and time x treatment interaction (p<0.01; F
(2.958, 17.09) = 5.364; epsilon = 0.33). Dunnett’s post hoc analysis showed a significant
reduction by 0.1 mg/kg MK-801 (p<0.01) at 60-, 90-, and 120-minutes time points, as compared
to vehicle + vehicle group. Haloperidol pretreatment showed no significant protective effect
against MK-801 induced reduction in ITC.
Furthermore, evoked power also showed a significant treatment effect (p<0.01; F (1.750,
12.25) = 13.46; epsilon = 0.58), and a significant time x treatment interaction (p<0.05; F (3.481,
20.11) = 2.98; epsilon = 0.39). However, there was no significant time effect (p=0.09; F (0.3250,
2.275) = 6.11; epsilon = 0.11). Post hoc analysis showed a significant reduction by 0.1 mg/kg
MK-801 (p<0.01) at 60-, 90-, and 120-minutes time points, as compared to vehicle + vehicle
group. However, haloperidol failed to show any protection against MK-801-induced reduction in
evoked power Fig 4.7 (A-D) shows heat maps and group summaries of ITC and evoked power.
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Figure 4.7. Effect of haloperidol pretreatment on MK-801-induced deficits in 40 Hz ASSR.
Heat-map summaries of ITC (A) and evoked power (B) of 40 Hz ASSR at 30 minutes after MK801 treatment. Group summaries of ITC (C) and evoked power (D) data at 30, 60, 90 and 120
minutes after MK-801 treatment. Data are from a group of 8 rats. Asterisks indicate significant
differences between vehicle + vehicle and vehicle + MK-801 groups (**p<0.01; Dunnett’s post
hoc, vehicle + MK-801 comparator). (ITC) inter-trial coherence.

Discussion
40 Hz ASSR is a candidate biomarker to test NMDAR- dependent neural synchrony in
the cortical circuits (Sivarao et al., 2016). Neural synchrony, which is an important prerequisite
for sensory-evoked gamma, plays an important role in attention, memory, and cognitive
processes (Fries et al., 2001; Gray et al., 1990; Landau and Fries, 2012). Thus, it is reasonable to
assume that disruption in the cortical synchrony in the form of ASSR may contribute to sensory
and cognitive deficits. Indeed, deficits in 40 Hz ASSR predict clinical outcomes in individuals at
high risk for schizophrenia as well as in patients (Grent-’t-Jong et al., 2021; Molina et al., 2020).
In addition to being a biomarker correlated with symptoms and functional outcomes, the
40 Hz ASSR may be also leveraged as an easily accessed neural synchrony marker that is also
robustly translational. The current body of literature indicates that 40 Hz ASSR may involve the
activity of cortical pyramidal-interneuron or the so-called PING networks that are also involved
in evoked gamma oscillations. For example, optogenetic driving of the layer 2/3 PV+ basket
cells result in a robust entrainment of these cells when the driving frequency is around 40 Hz.
Additionally, this also results in a robust increase in evoked field gamma oscillations (Cardin et
al., 2009). Moreover, genetic ablation in mice of the NR1 subunit, the obligatory component of
the heteromeric NMDAR, results in a specific deficit of gamma entrainment, centered ~ 40 Hz
(Carlén et al., 2012). Even more pertinent to our work, ASSR protocol in these NR1 mutant mice
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evoke a significantly attenuated ASSR response at 40 Hz. Lastly, we have shown that acute
NMDA antagonism also results in a robust and consistent attenuation of the 40 Hz ASSR
response (Raza and Sivarao, Sivarao et al.,2016, Sivarao et al., 2013). While it is clear that 40
Hz ASSR is highly susceptible to NMDA disruption, we have yet to see any data showing its
positive modulation to NMDA-based activation. The current work was done to test positive
modulation of the 40 Hz ASSR by several pharmacological approaches.
First, we tested D-serine, a co-agonist believed to be active endogenously at NMDA
receptors (Balu and Coyle, 2015). Indeed, several small clinical trials have demonstrated modest
positive effects on ameliorating schizophrenia symptoms in patients using this approach (Singh
and Singh, 2011). Interestingly, there is one small study that positively correlated endogenous Dserine levels in schizophrenia patients with evoked power of 40 Hz ASSR (Koshiyama et al.,
2019). No such correlation was seen in healthy controls. Overall, it is robust and convincing in
vivo data that show target engagement with D-serine treatment are lacking. As an attempt
towards filling this gap, we evaluated 40 Hz ASSR response both through dose-response studies
with D-serine as well as an attempted reversal of MK801-mediated disruption. As discussed in
the results section, we reported an unambiguous lack of response. It is unclear why this is the
case. For one, the therapeutic effect of D-serine in the small clinical trials alluded to above was
after several weeks of chronic treatment. It is possible that chronic treatment might have a better
outcome than the current result. However, it has been reported that hippocampal glycine site on
the NMDA receptors remains unsaturated and exogenous co-agonists can therefore augment
NMDA receptor function (Bergeron et al., 1998). Unfortunately, our data does not seem to
support this finding. At this time, it is unclear to us why this regimen was ineffective.
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Previous studies, however, have shown that D-serine may improve cognitive deficits
induced by NMDAR and acetylcholine receptor antagonists (Fone et al., 2020; Karasawa et al.,
2008). Similarly, pharmacological stimulation of GMS through D-serine shows ameliorative
effect on NMDAR-antagonist induced disruption in NMDAR function. (Gozzi et al., 2008)
However, in other studies, D-serine was unable to improve NMDAR antagonist-caused deficits
in sensory processing and stimulus-evoked gamma, which is consistent with our results (Hudson
et al., 2016). It is important to note that these studies used significantly higher doses of D-serine
(1-2 mg/kg) than the current study. Such high doses have been shown to also induce acute
nephrotoxicity in rodents (Hasegawa et al., 2019).
We tested clozapine and haloperidol for their effects on the 40 Hz ASSR. Interestingly, both
clozapine and haloperidol have been previously reported to acutely augment NMDA
transmission in vitro (Arvanov et al., 1997). Interestingly, using a steady state visual paradigm
that used photic stimulation at alpha (~10 Hz) frequency, it was reported schizophrenia patients
responsive to clozapine showed a robust enhancement in the steady state response, relative to
unresponsive patients who were also on clozapine (Jin et al., 1995). Based on these data, we
hypothesize that clozapine would augment the ASSR. Of course, clozapine is a notoriously
promiscuous drug that binds to a multitude of neurotransmitter receptors, including
dopaminergic, serotonergic, muscarinic, adrenergic and histaminergic receptors of varying
subtypes (Siafis et al., 2017). Thus, it would be a Herculean task to try todecipher what exactly
was the mechanism that enabled a dose-dependent and robust activation of the 40 Hz ASSR. At
this time, we are not able to pursue this line of research. Rather, we are reassured that 40 Hz
ASSR is a neural synchrony measure that can be bidirectionally and robustly modulated by
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pharmacological treatment. This is a very encouraging finding and lays the groundwork for
using 40 Hz ASSR as a pharmacodynamic biomarker for drug development studies in future.
To the best of our knowledge, this is the first study to test and report such effects of
clozapine on 40 Hz ASSR. Previous studies have reported that, as compared to any other
antipsychotics, clozapine showed improvement in neurophysiological (e.g., evoked gamma,
auditory evoked response (AER)) (Hudson et al., 2016; Umbricht et al., 1998), sensory-motor
gating (e.g., pre-pulse inhibition (PPI)) (Hudson et al., 2016) and cognitive performance
(Karasawa et al., 2008) function against NMDA antagonist-induced disruption. Moreover,
clozapine shows a distinct clinical profile that separates it from the rest of antipsychotics (Leucht
et al., 2013). It is highly effective against treatment-resistant schizophrenia, it improves cognitive
and negative symptoms, and schizophrenia patients voluntarily stay on clozapine treatment
regimen for far longer period than any other antipsychotic (Oh et al., 2020; Wagner et al., 2021).
Our results further add to the differentiated profile of clozapine in comparison with a typical
antipsychotic like haloperidol. It remains to be seen if this holds true with reference to atypical
antipsychotics as well, that share a similar spectrum of affinities to the list of neurotransmitter
receptors outlined above.
Although we focused only on EEG data from vertex for analyzing 40 Hz ASSR in the
above sections, preliminary analysis of frontal EEG data from the same rats showed some very
interesting effects of clozapine. For example, unlike the vertex response, the frontal ASSR
tended to evolve more slowly, taking about 200-250 ms to establish robust 40 Hz entrainment.
Clozapine, at all doses tested, showed a rapid entrainment relative to vehicle treatment. Indeed,
this happened 100-150 ms faster than it did with the vehicle group (supplementary Figure 4).
Moreover, this was not often associated with an increase in evoked power, particularly at lower
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doses. This observation in which synchrony improves without an accompanying increase in
signal power is a signature of “phase resetting” (Voloh & Womelsdorf, 2016). This entails,
endogenous on-going oscillations are resetting their on-going phase to embrace the new phase
(40 Hz). This is a very interesting research direction that has not been reported previously to be
associated with any pharmacological treatment. We look forward to following up on this in
future studies.
Haloperidol did not have the same effects as clozapine on the 40 Hz ASSR, despite the in
vitro observation that it improved NMDA transmission (Arvanov et al., 1997). In the above
paper, although haloperidol improved NMDA transmission, it did it at concentrations that were
3-5-fold greater than that of clozapine (Arvanov et al., 1997). Thus, it is possible that a higher
dose of haloperidol would have shown an effect on NMDA transmission. However, we were
careful to use only doses that were not associated with motoric side effects of antipsychotic
drugs and were anchored to dose levels associated with clinically relevant D2 occupancy (Kapur
et al., 2000). Doses above 0.1 mg/kg of haloperidol are associated with catalepsy in rats
(Wadenberg et al., 2001).
In summary, this study showed that only clozapine, at acute concentrations that are
comparable to clinical steady state concentrations, showed a robust augmentation of the 40 Hz
ASSR. Although clozapine appears to mediate at least part of its effects by accelerating the phase
resetting of on-going neural oscillations, it is not possible to predict the exact molecular
mechanism for this without extensive and further research. For now, it is exciting to note that 40
Hz ASSR can be dose-dependently and bidirectionally modified by pharmacological treatments.
These are promising results in further establishing this measure of evoked gamma synchrony as a
potential pharmacodynamic biomarker. Once validated, such tools are invaluable in guiding
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preclinical candidate selection, dose selection in early clinical development, and may be even
useful for patient stratification and proof of concept studies.
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CHAPTER 5. SUMMARY AND DISCUSSION
Currently available antipsychotics have limited efficacy and show many undesirable and
even dangerous side effects (Miyamoto et al. 2012). Safer and more efficacious drug
development has been hampered by a lack of disease-specific and well-validated preclinical
models. On the other hand, clinical development has been hampered by a lack of objective
biomarkers and modest effect sizes of treatments that get further diluted by between-subject trial
designs with high intersubject variance. Additionally, a lack of objective biomarkers impact
meeting drug developmental benchmarks such as target engagement, lead selection, dose
selection, and patient stratification, affecting the probability of success for novel treatments
(Subramanyam and Goyal 2016). This research outlines a way forward to address some of these
challenges.
Due to the unknown etiology and complex nature of schizophrenia, faithfully replicating
human symptoms in animals presents a formidable challenge (Hyman 2013). Many currently
used animal models rely on behavioral tests like sucrose preference, social withdrawal, Morris
water maze, conditional avoidance response, and psychomotor measures like hyperlocomotion
and stereotypic behavior, to model the core symptom domains of schizophrenia. How relevant
these models are to schizophrenia, an essentially human illness, has been questioned (Nestler and
Hyman 2010). In this context, endophenotypes that are specific neurophysiological responses
associated with a genetic risk of schizophrenia on one hand and the disease symptoms on the
other hand, but are also conserved across mammals, may serve as an alternative strategy to
model disease-related circuit dysfunction.
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Evoked gamma oscillations in the form of the 40 Hz ASSR are an emerging cortical
circuit endophenotype that we chose for this dissertation research. In addition to being
translatable, measures like gamma oscillations bring new insight into cortical circuit-level effects
of pharmacological intervention, thus providing a clear neurobiological substrate for the drug
development process. Moreover, as our research has demonstrated, such tools are especially
suitable for within-subject trial design that can curb the high variance associated with psychiatric
clinical trials that use a between-subject design (Salkind 2010).
In the present work, we first tested the reliability of tone-evoked gamma oscillations and
40 Hz ASSR from vertex recordings in a repeated measures design. 40 Hz ASSR showed better
test-retest reliability as compared to tone evoked gamma response. However, both tone-evoked
gamma and 40 Hz ASSR were equally sensitive to the disruption by NMDA antagonist, MK801’s disruption. This might suggest that the repeated measures design may not be as suitable for
tone-evoked gamma studies as it is for 40 H ASSR. However, notwithstanding the lower ICC,
tone-evoked gamma was just as sensitive to MK801 as 40 Hz ASSR. This is likely due to the
large effect size of the treatment. Thus, if the effect size of a drug treatment, for example, as
measured by Cohen’s d, is large enough, it can overcome the test-retest variability. This is a key
message we can draw from these studies.
In preclinical literature, 40 Hz ASSR is recorded from several regions like the midpoint
of the skull or the vertex, temporal region, or the frontal region. It remains to be established
whether one region is better than the other in terms of response reliability as well as sensitivity to
drug treatment. We tested the reliability of 40 Hz ASSR recorded from the vertex and temporal
regions. This study confirmed the good test-retest reliability of vertex 40 Hz ASSR as discussed
above as well as its high sensitivity to MK801. This is an encouraging finding as assays that are
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amenable to drug development studies need to be stable and consistent enough in their
performance over time, such that leads tested at different times can be compared and prioritized.
However, 40 Hz ASSR recording from the temporal area showed poor test-retest reliability as
well as a poor sensitivity to MK-801 treatment. Since the temporal cortex represents the auditory
primary cortex and the retrosplenial cortex underlying the vertex represents the secondary
association cortex, we could speculate that integrative functions such as might occur in the
associative cortices may be more vulnerable to NMDA antagonism-mediated disruption, relative
to the primary sensory cortex. Indeed, we have previously observed that mismatch negativity
was more robust and disrupted more readily at the vertex than at the primary auditory cortex
(Sivarao et al. 2014).
Since we have clearly and repeatedly demonstrated that 40 Hz ASSR is highly vulnerable
to NMDA antagonism, we asked the question if NMDA channel co-agonists can augment the 40
Hz ASSR response. Despite testing a range of doses of D-serine, a co-agonist at the NMDA
receptor, we found no evidence for augmentation. The doses we chose, and the protocol of
dosing were previously shown to robustly increase D-serine levels in the brain (Hasegawa et al.
2019). Thus, it is clear from our studies that D-serine had no effect on modulating the ASSR
transmission. Previous studies have provided evidence that endogenous D-serine at the NMDA
receptors is present at a sub-saturation level and that exogenous increases in D-serine would
increase NMDA receptor activation (Bergeron et al. 1998). However, we saw no functional
evidence for this as we used a dose range and dosing protocol that was shown to robustly
increase D-serine levels in the rat brain (Hasegawa et al. 2019). Of course, we did not directly
measure D-serine concentration or NMDA receptor function but only relied on the 40 Hz ASSR
measure. Indeed, Matsui and colleagues (1995) observed that in a microdialysis study that D145

serine levels were at saturation vis-a-vis the NMDA receptors in the rat frontal cortex (Matsui et
al. 1995).
In the next part of the study, we tested the effects of two prototypical antipsychotics,
haloperidol, and clozapine, on the 40 Hz ASSR. In the literature, it is typical to disrupt native
neurophysiological processes such as sensory gating or PPI pharmacologically or through
genetic manipulation and protect or reverse the deficit through pre- or post-treatment
respectively with an antipsychotic (Swerdlow and Geyer 1993). Here, we were more interested
in seeing the effect of the antipsychotic drugs by themselves. This is because both clozapine and
haloperidol were shown to augment NMDA neurotransmission in vitro (Arvanov et al. 1997).
Since we have a highly sensitive assay for NMDA blockade, we thought it might also be
sensitive to any presumable NMDA augmentation.
In the preclinical literature, it is not unusual to encounter doses of antipsychotic drugs
that have little relationship with clinically relevant exposures and therefore therapeutic effects.
For example, a commonly used dose of haloperidol in rodents may be as high as 1 mg/kg (Kapur
et al. 2000). It is unclear what this dose represents since the D2 occupancy relevant for
antipsychotic effect is achieved by a dose that is at least 10 times smaller (ie., <0.1 mg/kg).
Moreover, when haloperidol’s D2 occupancy exceeds 80%, achieved by a 0.1 mg/kg dose or
higher, robust cataleptic effects are seen. When evaluating the in vivo effects of clozapine and
haloperidol, we were careful to choose only those doses that are reflective of clinically observed
D2 occupancy. This was important since we wanted to know if the potential NMDA mechanism
was operational at therapeutically relevant doses.
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Clozapine robustly improved the 40 Hz ASSR phase locking, while haloperidol had no
effect on the ASSR measures. Additionally, clozapine augmentation was most obvious on the
interatrial coherence measure whereas the effect on evoked power was inconsistent, particularly
at the low doses. This suggests that clozapine works by causing the phase resetting of the
oscillatory signal, rather than increasing the neural recruitment (Canavier 2015), an emerging
tool to study information processing in the brain. This is an unprecedented observation and may
offer a fundamentally new insight into how clozapine, a drug that stands out from all other
antipsychotics in terms of its superior efficacy profile, has a differentiated profile relative to
other antipsychotic agents (Nucifora et al. 2017). In future, we plan to test other atypical drugs
like olanzapine or risperidone, to see if this feature is shared across other antipsychotic drugs that
share a broad-spectrum affinity for neurotransmitter receptors, or it is truly unique to clozapine.
In our current work, we used female Sprague Dawley rats for hypotheses testing. The
effect of gender on 40 Hz ASSR has not been studied in detail. Previous studies have shown
gender-specific differences in auditory-evoked responses like ABR in humans that are reflective
of network responses at the level of the brain stem (Skoe and Kraus 2010). For ABRs, females
tend to show stronger responses with shorter latencies as compared to males (Dehan and Jerger
1990; McFadden et al. 2010). In contrast, we are not aware of many studies that documented sex
differences for the 40 Hz ASSR. However, we are aware of one study that tested the effects of
the menstrual cycle on 40 Hz ASSR in females. It showed that 40 Hz ASSR amplitude was
associated with estrogen levels. The amplitude and ITC of 40 Hz increased with increased levels
of estrogen (Inga et al. 2014). It has also been reported that 40 Hz ASSR is gender-specific based
on handedness. Left-handed females showed significantly lower phase synchrony as compared to
left-handed males (Melynyte et al. 2018). However, there is no report of any gender-specific
147

differences in 40 Hz ASSR in rodent studies in the literature. In the current study, we did not see
any change in any measures of the 40 Hz ASSR across time in female control rats. Our results
from test-reliability studies further support the consistency of 40Hz ASSR over the period of
three weeks (i.e., the maximum length of time we recorded). We housed female rats alone in the
cages. Although we did not determine the estrous phase or measure estrogen levels, it is possible
that single housing induced an anestrous phase in these rats, leading to no obvious observable
differences over time. However, this is something that deserves more attention in future studies.
The NMDA receptor hypofunction hypothesis has been proposed as an alternative to the
dopamine hypothesis as a pathological model for schizophrenia (Olney and Farber 1995; Goff
and Coyle 2001). Consistent with this hypothesis, acute dosing with NMDA antagonists elicits a
full spectrum of behavioral changes that are reminiscent of positive, negative, and cognitive
symptoms seen in schizophrenia patients (Javitt and Zukin 1991; Krystal et al. 1994). In the
current work, we implemented an acute pharmacological model by treating rats with MK-801.
Adell and colleagues (2012) have argued that this model has reasonable face, construct, and
predictive validity (Adell et al. 2012). Briefly, acute MK-801 administration results in behavioral
phenotypes like hyperlocomotion, stereotypic behavior (head weaning, circumambulation), and
cognitive deficits of different sorts, which are considered a surrogate for positive and cognitive
symptoms in schizophrenia. Furthermore, results from current work have shown that MK-801
dose-dependently reduced 40 Hz ASSR in female rats, consistent with 40 Hz ASSR deficits seen
in schizophrenia patients (Thuné et al. 2016). At a cellular level, systemic administration of
NMDA antagonists appears to cause a temporary loss of the function of PV+ interneurons as
evidenced by an increase in background gamma (disinhibition) and a reduction in evoked gamma
(Hakami et al. 2009). Furthermore, behavioral, neurochemical, and neurophysiological
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(including 40 Hz ASSR, as shown in current work) alterations induced by acute MK-801
administration are responsive to antipsychotics. As compared to other NMDAR blockers like
ketamine, and PCP, MK-801 has a substantially higher receptor affinity and duration of the
blockade, making it a convenient tool for causing a disruption in NMDA transmission over a
period of several hours (Davies et al. 1988; Miyamoto et al. 2000; Pinault 2008; Hakami et al.
2009). Moreover, NMDA antagonists like ketamine show rapid kinetics and as a result, also
show a variable response over time (Plourde et al. 1997; Sivarao et al. 2016), making it
challenging to use with bolus dosing. However, research groups have used ketamine delivery
through intravenous infusion regimens to avoid the rapid change in drug concentrations
associated with a bolus injection of ketamine (Haaf et al. 2022).
It is proposed that deficits in information processing lead to the functional impairment
experienced in schizophrenia. Thus, neurophysiological biomarkers that can probe the functional
integrity of neural structures involved in information processing have gained interest. These
include sensory gating, sensorimotor gating (e.g., pre-pulse inhibition (PPI), mismatch negativity
(MMN), and others. Abnormalities in the thalamic gating, especially in the corticostriatothalamocortical circuitry may result in sensory overload and cause cognitive deficits. NMDA
antagonists have been shown to cause a reduction in sensory gating as well as sensorimotor
gating measures. However, these neurophysiological biomarkers tend to show an all or none
effect of the pharmacological intervention, owing to the lack of a robust gradation in response. In
contrast, 40 Hz ASSR shows a robust dose-dependent and linear effect of MK-801 treatment,
thus highlighting an advantage of this assay over other assays like sensory gating or mismatch
negativity.
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Moreover, these endophenotypes may each index activity in unique and distinct neural
circuits. For example, sensory gating has been attributed to the hippocampal inhibitory
mechanism (Bickford et al. 1993), while PPI reflects the activity of a limbic cortex, striatum,
pallidum, and pontine tegmentum (CSPP) circuit (Swerdlow et al. 2001). On the other hand,
local field potential (LFP) studies have shown layers 2/3 and 4 as the generators of 40 Hz ASSR
and mismatch negativity (Javitt and Sweet 2015; Funk et al. 2020). This aligns with the cortical
layers that give rise to gamma oscillations (Welle and Contreras 2016). Moreover, molecular
disruption of NMDA transmission through NR1 deletion in layers 2/3 specifically affects the
ability to entrain at gamma frequencies but not at lower frequencies (Cardin et al. 2009; Carlén et
al. 2012; Nakao and Nakazawa 2014). These superficial layers in the cortex play an essential role
in sensory processing (Quiquempoix et al. 2018) and cognitive function (e.g., working memory),
processes affected in schizophrenia. Moreover, layers 2/3 have centrifugal projections, which
play an important role in integrating sensory information across different brain regions
(Yamashita et al. 2018). Interestingly, layers 2/3 are also the cortical layers where schizophrenia
patients most consistently exhibit GABAergic deficits suggesting that the cellular machinery
required for normal cognitive and sensory function including for generating gamma oscillations
is damaged (Beneyto et al. 2011). Thus 40 Hz ASSR can be used as a tool to probe the structural
and functional integrity of this specific region. From a drug discovery point of view, such
endophytopic assays are complementary as they represent neural function in distinct and nonredundant circuits. Additionally, they may underlie distinct phenotypes as well. For example,
sensory gating deficits may be a neurophysiological manifestation of the perceptual
abnormalities (“sensory inundation”), a common complaint from schizophrenia patients (Scheydt
et al. 2017). On the other hand, gamma oscillatory deficits in the prefrontal cortex may be an
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endophenotypic manifestation of the working memory deficits that schizophrenia patients and
patients with other diagnoses such as bipolar depression, may experience (Singh et al. 2020).
Having distinct assays indexing functionally distinct symptoms would also help in identifying
patient subgroups and stratifying them according to their specific deficits and symptoms. Such
sub-classification is especially relevant for schizophrenia since it is believed that often
psychiatric subjects with distinct disease subtypes are clubbed as one due to a lack of specific
and discriminating tools (Carpenter et al. 1976). Such subgrouping may be a starting point for
more personalized treatments, rather than a “one size fits all” approach that is currently the
practice (Donati et al. 2020).
In general, antipsychotics often take several weeks to reach their full therapeutic effect in
human patients. Yet, in our rodent studies, we saw robust effects of clozapine on the 40 Hz
ASSR within an hour after administration. Are these changes a mere epiphenomenon that have
no relationship to therapeutic effect? First, while peak clinical benefit may take weeks,
antipsychotic drugs do have a rapid onset (Kapur et al. 2005). This is the reason why they are a
staple in every emergency medicine department. However, it was historically thought that the
immediate effects are non-specific, and the pharmacological effects take a much longer time to
start (Gelder et al. 2012). This perception has been recently challenged using placebo controlled
clinical trials. For example, Kapur and colleagues (2005) have shown, using a placebo-controlled
multi-center randomized clinical trial that olanzapine showed efficacy within 2 h after
administration in acutely psychotic patients while haloperidol’s effect was apparent within the
first 24 hours (Kapur 2005). Moreover, D2 receptor occupancy of a PET tracer was already at its
peak in several subjects, only 3 h after dosing (Nordström et al. 1992). Since 3 h was the earliest
time point for evaluation in this study, it is conceivable that the actual peak effect may have been
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even earlier. Thus, D2 occupancy and clinical antipsychotic effects can be observed within hours
after antipsychotic drug administration. While it is premature to consider 40 Hz ASSR as a
measure of efficacy, the time scale for ASSR effects we observed after clozapine administration
is not inconsistent with the rapid onset of therapeutic effects outlined above.
Overall, in this work, we have established that vertex recorded 40 Hz ASSR has a good
test-retest reliability and that it is exquisitely sensitive to NMDA inhibition. Additionally, we
discovered that clozapine augments 40 Hz ASSR and the likely mechanism for this could be
through improving phase resetting including how quickly the 40 Hz ASSR entertainment
happens, relative to the stimulus onset. By showing that we have a reliable neural synchrony
measure in the form of a 40 Hz ASSR that can be bidirectionally altered using pharmacological
tools, we believe that we have further fortified the characterization of the 40 Hz ASSR as a
pharmacodynamic biomarker of cortical neural synchrony. Translational cortical circuit
performance tools such as the 40 Hz ASSR will enable preclinical drug development through
identifying and prioritizing molecules based on objective indices (e.g., neural synchrony), that
are quantifiable, dose-related, and relevant to higher-order information processing. Clinically,
such tools can help in confirming CNS exposure, choosing an appropriate dose, and identifying
patient cohorts most likely to benefit from an intervention such as improving evoked gamma
response. These are drug development process signposts that can enable the overarching goal of
finding more effective and safer treatments for troubling mental illnesses.
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APPENDICES
Appendix A: Supplementary Figure 1
Line plots showing the mean RMS-amplitude value for tone-evoked response (left panel) and 40
Hz ASSR (right panel) for each animal, across six sessions (N=12). Notice a greater variability
in tone-evoked gamma vs. 40 Hz ASSR.
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Appendix B: Supplementary Figure 2
Comparison of latencies for P1, N1, and P2 in unfiltered 40 Hz ASSR recordings from vertex and temporal regions. The waveforms
depict a grand average of 12 rats. Both vertex and temporal ERP responses show similar latencies for P1, N1 and P2, as shown
below, indicating that they may represent two parallel rather than serial sources.

P2

250 uV

P1

N1

Stimulus Onset
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Appendix C: Supplementary Figure 3
Breakdown of averaged 40 Hz click train-evoked response into AER (auditory-evoked response), and an SSR (steady-state response).
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Appendix D: Supplementary Figure 4
Narrow band filtered (35-45 Hz) overlay of 40 Hz ASSR averages from 10 rats from the frontal lead, after vehicle or 5 mg/kg
clozapine treatment. Left panel shows random/asynchronous activity during a 200 msec period (boxed) in vehicle group, whereas the
clozapine group shows robust and early onset entrainment. Inset demonstrates the same at an enhanced temporal resolution. This
neurophysiological evidence for clozapine-mediated phase resetting is unprecedented in literature.
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